U.S. patent application number 10/743051 was filed with the patent office on 2005-06-23 for wound dressing and method for controlling severe, life-threatening bleeding.
Invention is credited to Campbell, Todd D., McCarthy, Simon J., Wiesmann, William P..
Application Number | 20050137512 10/743051 |
Document ID | / |
Family ID | 34678562 |
Filed Date | 2005-06-23 |
United States Patent
Application |
20050137512 |
Kind Code |
A1 |
Campbell, Todd D. ; et
al. |
June 23, 2005 |
Wound dressing and method for controlling severe, life-threatening
bleeding
Abstract
This invention is directed to advanced hemorrhage control wound
dressings, and methods of using and producing same. The subject
wound dressing is constructed from a non-mammalian material for
control of severe bleeding. The wound dressing for controlling
severe bleeding is formed of a biomaterial comprising chitosan, a
hydrophilic polymer, a polyacrylic polymer or a combination
thereof. The kind of severe, life-threatening bleeding contemplated
by this invention is typically of the type not capable of being
stanched when a conventional gauze wound dressing is applied with
conventional pressure to the subject wound. The wound dressing
being capable of substantially stanching the flow of the severe
life-threatening bleeding from the wound by adhering to the wound
site, to seal the wound, to accelerate blood clot formation at the
wound site, to reinforce clot formation at the wound site and
prevent bleed out from the wound site, and to substantially
prohibit the flow of blood out of the wound site.
Inventors: |
Campbell, Todd D.;
(Petaluma, CA) ; Wiesmann, William P.;
(Washington, DC) ; McCarthy, Simon J.; (Portland,
OR) |
Correspondence
Address: |
BURNS DOANE SWECKER & MATHIS L L P
POST OFFICE BOX 1404
ALEXANDRIA
VA
22313-1404
US
|
Family ID: |
34678562 |
Appl. No.: |
10/743051 |
Filed: |
December 23, 2003 |
Current U.S.
Class: |
602/41 |
Current CPC
Class: |
A61P 17/02 20180101;
A61L 15/425 20130101; A61F 2013/00472 20130101; A61F 13/0226
20130101; A61F 13/0223 20130101; A61F 17/00 20130101; A61F 13/0276
20130101 |
Class at
Publication: |
602/041 |
International
Class: |
A61F 013/00; A61F
015/00 |
Claims
1. A compressed sponge for hemorrhage control comprising a
hydrophilic polymer, wherein the compressed sponge has a compressed
sponge density of about 0.6 to 0.15 g/cm.sup.3; and wherein the
hydrophilic polymer is a polyacrylic acid.
2. The compressed sponge of claim 1, wherein the compressed sponge
further comprises an active ingredient.
3. The compressed sponge of claim 2, wherein the active ingredient
is calcium, thrombin, factor VIIa, factor XIII, thromboxane A2,
prostaglandin-2a, epidermal growth factor, platelet derived growth
factor, Von Willebrand factor, tumor necrosis factor (TNF),
TNF-alpha, transforming growth factor (TGF), TGF-alpha, TGF-beta,
insulin like growth factor, fibroblast growth factor, keratinocyte
growth factor, nerve growth factor, penicillin, ampicillin,
methicillin, amoxycillin, clavamox, clavulanic acid, amoxicillin,
aztreonam, imipenem, streptomycin, Kanamycin, Tobramycin,
gentamicin, vancomycin, clindamycin, erythromycin, polymyxin,
bacitracin, amphotericin, nystatin, rifampicin, tetracycline,
doxycycline, chloramphenicol or a combination thereof.
4. A compressed composite sponge for hemorrhage control comprising
a hydrophilic polymer sponge and a wettable polymer matrix or
wettable polymer matrices inside the sponge and/or at the sponge
surface; and wherein the hydrophilic polymer is polyacrylic
acid.
5. The compressed composite sponge of claim 4, wherein the wettable
polymer matrices are selected from the group consisting of a
non-woven mat, a woven mat, a molded polymer mesh, and a low
density sponge.
6. The compressed composite sponge of claim 5, wherein the wettable
polymer matrix is selected from the group consisting of a chitin,
an alginate, a neutralized chitosan, a re-acetylated chitosan, a
poly(glycolic acid), a poly(lactic acid), a poly(e-caprolactone), a
poly(.beta.-hydroxybutyric acid), a poly(.beta.-hydroxyvaleric
acid), a polydioxanone, a poly(ethylene oxide), a poly(malic acid),
a poly(tartronic acid), a polyphosphazene, a polyethylene, a
polypropylene, a metallocene polymer, a polyurethane, a
polyvinylchloride polymer, a polyester, a polyamide and a
combination thereof.
7. The compressed composite sponge of claim 4, wherein the sponge
comprises a textile thread impregnated with a hydrophilic
polymer.
8. The compressed composite sponge of claim 7, wherein the textile
thread is impregnated with a hydrophilic polymer, and wherein the
hydrophilic polymer is a polyacrylic acid.
9. The compressed composite sponge of claim 4, wherein the wettable
polymer matrice is a non-woven mesh.
10. The compressed composite sponge of claim 4, wherein the sponge
contains pores with pore diameters of about 15 microns to about 300
microns.
11. The compressed composite sponge of claim 4, wherein the sponge
contains pores with pore diameters of about 30 microns to about 250
microns.
12. The compressed composite sponge of claim 4, wherein the sponge
contains pores with pore diameters of about 100 microns to about
225 microns.
13. The compressed composite sponge of claim 4, wherein the sponge
contains pores with pore diameters of about 125 microns to about
200 microns.
14. The compressed composite sponge of claim 4, wherein the sponge
contains pores with pore diameters of about 150 microns to about
175 microns.
15. The compressed composite sponge of claim 4, wherein the sponge
has an available blood contacting surface area per base surface of
the sponge of about 100 cm.sup.2 per cm.sup.2 to about 1000
cm.sup.2 per cm.sup.2.
16. The compressed composite sponge of claim 4, wherein the sponge
has an available blood contacting surface area per base surface of
the sponge of about 200 cm.sup.2 per cm.sup.2 to about 800 cm.sup.2
per cm.sup.2.
17. The compressed composite sponge of claim 4, wherein the sponge
has an available blood contacting surface area per base surface of
the sponge of about 300 cm.sup.2 per cm.sup.2 to about 500 cm.sup.2
per cm.sup.2.
18. The compressed composite sponge of claim 4, wherein the
compressed composite sponge further comprises a backing support
layer.
19. The compressed composite sponge of claim 18, wherein the
backing support layer is a layer of polymeric material.
20. The compressed composite sponge of claim 19, wherein the
polymeric material is a synthetic biodegradable material or a
naturally occurring biodegradable polymer.
21. The compressed composite sponge of claim 20, wherein the
synthetic biodegradable material is selected from the group
consisting of poly(glycolic acid), poly(lactic acid),
poly(e-caprolactone), poly(.beta.-hydroxybutyric acid),
poly(.beta.-hydroxyvaleric acid), polydioxanone, poly(ethylene
oxide), poly(malic acid), poly(tartronic acid), polyphosphazene,
the copolymers of the monomers used to synthesize said polymers and
combinations thereof.
22. The compressed composite sponge of claim 20, wherein the
naturally occurring biodegradable polymers are selected from the
group consisting of chitin, algin, a starch, dextran, collagen,
albumen, and combinations thereof.
23. The compressed composite sponge of claim 19, wherein the
synthetic non-biodegradable material is selected from the group
consisting of polyethylene, polypropylene, a metallocene polymer, a
polyurethane, a polyvinylchloride polymer, a polyester, a polyamide
and a combination thereof.
24. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has a degree of adhesion to the wound
site of about 40 kPa to 500 kPa.
25. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has a degree of adhesion to the wound
site of about 60 kPa to 250 kPa.
26. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has a degree of adhesion to the wound
site of about 100 kPa to 200 kPa.
27. The compressed composite sponge of claim 4, wherein the
compressed composite sponge is capable of forming an adhesive
material in combination with blood flowing from said wound at a
wound dressing-blood interface.
28. The compressed composite sponge of claim 27, wherein the
adhesive material preferably has a pH of not less than about 5.5
when the wound is sealed.
29. The compressed composite sponge of claim 27, wherein the
adhesive material preferably has a pH of not less than about 6.5
when the wound is sealed.
30. The compressed composite sponge of claim 27, wherein the
adhesive material preferably has a pH of not less than about 7.5
when the wound is sealed.
31. The compressed composite sponge of claim 27, wherein the
adhesive material comprises an acid selected from the group
consisting of acetic acid, formic acid, lactic acid, ascorbic acid,
hydrochloric acid and citric acid.
32. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has a thickness which is not less than
about 3.0 mm and not more than about 8 mm.
33. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has a thickness which is not less than
about 3.5 mm and not more than about 7 mm.
34. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has a thickness which is not less than
about 4.0 mm and not more than about 6 mm.
35. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has an ultimate tensile stress about
0.1 MPa to about 10 MPa.
36. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has an ultimate tensile stress of about
0.15 MPa to about 0.8 MPa.
37. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has an ultimate tensile stress of about
0.25 MPa to about 0.5 Mpa.
38. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has an ultimate elongation of about
5%.
39. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has an ultimate elongation of about
10%.
40. The compressed composite sponge of claim 4, wherein the
compressed composite sponge has an ultimate elongation of about
15%.
41. A process for preparing a compressed sponge for hemorrhage
control of claim 1 comprising: (a) freezing/freeze drying a low
density sponge; and (b) compressing the low density sponge at about
10 mm per minute, and at about 80.degree. C., to thereby obtain a
compressed sponge with a density of about 0.1 to about 0.2
g/cm.sup.3.
42. A process for preparing a compressed sponge for hemorrhage
control of claim 1 comprising: (a) compressing a low density sponge
at a rate of about 10 mm per minute, at about 80.degree. C., to
thereby obtain a compressed sponge with a density of about 0.1 to
about 0.2 g/cm.sup.3, and wherein said low density sponge is not
frozen or freeze-dried prior to compressing.
43. The process of claim 42, wherein the low density sponge has a
density of less than 0.035 g/cm.sup.3 to about 0.01 g/cm.sup.3.
44. The process of claim 42, wherein the compressed sponge has a
density of about 0.15 g/cm.sup.3 to about 0.1 g/cm.sup.3.
45. A process for preparing a compressed composite sponge of claim
4 for hemorrhage control comprising: a) degassing a biomaterial
solution by heating the biomaterial solution and applying a vacuum
thereto; b) freezing the degassed biomaterial solution; c) removing
water from within frozen biomaterial without damaging the
structural integrity of the frozen biomaterial so that the water in
the biomaterial passes from a solid phase into a gas phase; d)
compressing the biomaterial at a rate of about 10 mm per minute to
obtain a compressed sponge with a density of about 0.1 to about 0.2
g/cm.sup.3; and e) baking the compressed sponge at 80 degrees C.
for 30 minutes.
46. The process of claim 45, wherein the temperature is gradually
lowered over a predetermined period of time during the freezing of
the biomaterial of step (b).
47. The process of claim 45, wherein the temperature of step (b) is
a final freezing temperature of not more than about -5.degree.
C.
48. The process of claim 45, wherein the temperature of step (b) is
a final freezing temperature of not more than about -35.degree.
C.
49. The process of claim 45, wherein the temperature of step (b) is
a final freezing temperature of not more than about -25.degree.
C.
50. The process of claim 45, wherein the water removal is performed
by freeze-drying the frozen biomaterial.
51. The process of claim 45, further comprising the step of adding
gases selected from the group consisting of argon, nitrogen and
helium back into the degassed chitosan solution before the
freezing.
52. The process of claim 45, wherein the compressed sponge is
sterilized.
53. The process of claim 45, wherein the compressed sponge is
sterilized by gamma irradiation.
54. A method of preventing severe bleeding in a subject comprising
administering a compressed sponge of claim 1 or a compressed
composite sponge of claim 4.
55. The method of claim 54, wherein the subject is a mammal.
56. The method of claim 55, wherein the mammal is human.
57. The method of claim 54, wherein the subject is suffering from
severe bleeding such that about 30-40% total blood loss would
result within 20 to 30 minutes if the bleeding was left
uncontrolled.
58. The method of claim 54, wherein the compressed sponge or
compressed composite sponge is applied with about 60 to 80 kPa
pressure directly to a bleeding wound and held in place for 3 to 5
minutes before releasing, packing and wrapping the bleeding
wound.
59. A bandage kit for treating severe bleeding comprising the
compressed sponges of claim 1 or the composite compressed sponges
of claim 4, a gauze roll for packing and an Ace bandage for
wrapping a wound.
60. A process for mechanical mating and meshing the sponges of
claims 1 and 4 comprising pressing tissue contacting sides of the
sponge against a macrotextured surface.
61. The process of claim 60, wherein the macrotextured surface is
selected from the group consisting of surfaces prepared by chemical
etching, surfaces prepared by ion beam surface ablation, surfaces
prepared by mechnical cutting, and surfaces prepared by laser
ablation.
62. A process for improving the mechanical traction of the sponges
of claims 1 and 4 comprising pressing tissue contacting sides of
the sponge against a macrotextured surface.
63. The process of claim 62, wherein the microtextured surface is
selected from the group consisting of surfaces prepared by chemical
etching, and surfaces prepared by particle blasting techniques.
64. A process for limiting or stopping the formation of coarse
crust on the surface of a sponge of claim 1 or 4, comprising
covering the surface of the sponge with a polymer film, a polymer
plate, an elevated plastic plate, or a moisture impermeable,
breathable membrane film.
65. A compressed low density sponge, wherein a sponge with a
density of about less than 0.05 g/cm.sup.3 is compressed until the
sponge reaches a density of about less than 0.08 g/cm.sup.3, and
wherein the compressed, low density sponge is not frozen or
freeze-dried prior to compression.
66. The low density sponge of claim 65, wherein the sponge is
subjected to a phase inversion process, a foaming technique or
covalent binding of active components to preformed matrices prior
to compression of the sponge.
67. The compressed sponge and compressed composite sponge of claim
1 or 4, wherein the sponge further comprises a hydrophilic
polymer.
68. The compressed sponge and compressed composite sponge of claim
67, wherein the hydrophilic polymer is selected from the group
consisting of alginate, chitosan, a hydrophilic polyamine, a
chitosan derivative, polylysine, polyethylene imine, xanthan,
carrageenan, quaternary ammonium polymer, chondroitin sulfate, a
starch, a modified cellulosic polymer, a dextran, hyaluronan and a
combination thereof.
69. The compressed sponge and compressed composite sponge of claim
68, wherein the starch is selected from the group consisting of
amylase, amylopectin and a combination of amylopectin and
amylase.
70. The compressed sponge and compressed composite sponge of claim
67, wherein the hydrophilic polymer is chitosan.
Description
FIELD OF THE INVENTION
[0001] This invention is directed to hemorrhage control wound
dressings, and methods of using and producing such dressings. The
subject wound dressing is constructed from a non-mammalian material
for the control of severe bleeding. The wound dressing is formed of
a biomaterial comprising chitosan and/or other hydrophilic polymers
for controlling severe bleeding. The material may alternatively
comprise polyacrylic acid or a combination of polyacrylic acid with
other polymers. The kind of severe, life-threatening bleeding
contemplated by this invention is of the type not capable of being
stanched when a conventional gauze wound dressing is applied with
conventional pressure to the wound. The wound dressing is capable
of substantially stanching the flow of life-threatening bleeding
from a wound by adhering to the wound site, sealing the wound,
accelerating blood clot formation at the wound site, reinforcing
clot formation at the wound site, preventing bleed out from the
wound site, and substantially prohibiting the flow of blood out of
the wound site.
BACKGROUND OF THE INVENTION
[0002] An advanced hemorrhage control bandage and methods of its
application would substantially augment available hemostatic
methods. To date, the application of continuous pressure with gauze
bandage remains the preferred primary intervention technique used
to stem blood flow, especially flow from severely bleeding wounds.
However, this procedure neither effectively nor safely stanches
severe blood flow. This has been, and continues to be, a major
survival problem in the case of severe life-threatening bleeding
from a wound.
[0003] Furthermore, it is widely accepted that severe bleeding is
the leading cause of death from wounds on the battlefield,
accounting for approximately 50 percent of such deaths. It is
estimated that one-third of these deaths could be preventable with
enhanced hemorrhage control methods and devices. Such enhanced
hemorrhage control would also prove very useful in non-military
settings, e.g., hospitals and veterinary clinics, where hemorrhage
is the second leading cause of death following trauma.
[0004] Currently available hemostatic bandages such as collagen
wound dressings or dry fibrin thrombin wound dressings are
restricted to use in surgical applications, and are not
sufficiently resistant to dissolution in high blood flow. They also
do not possess enough adhesive properties to serve any practical
purpose in the stanching of severe blood flow. These currently
available surgical hemostatic bandages are also delicate and thus
prone to failure should they be damaged by bending or loading with
pressure. They are also susceptible to dissolution in hemorrhagic
bleeding. Such dissolution and collapse of these bandages may be
catastrophic, because it can produce a loss of adhesion to the
wound and allow bleeding to continue unabated.
[0005] There is prior art relating to chitosan and chitosan
dressings. For example, U.S. Pat. No. 4,394,373 issued to Malette
et al. employs chitosan in liquid or powder form to agglutinate
blood in microgram/mL quantities. Also, U.S. Pat. No. 4,452,785
issued to Malette et al. is directed to a method of occluding blood
vessels therapeutically by injecting chitosan directly into the
vessels. U.S. Pat. No. 4,532,134 issued to Malette et al. further
relates to hemostatis, inhibiting fibroplasias, and promoting
tissue regeneration by placing in contact with the tissue wound a
chitosan solution or water-soluble chitosan. The chitosan forms a
coagulum, which prevents bleeding.
[0006] U.S. Pat. No. 5,858,350 issued to Vournakis et al. relates
to a process to make diatom derived biomedical grade, high purity
chitin and chitin derivatives (so called protein-free even though
this is not demonstrated by analysis in the patent). The proposed
advantage of so called protein-free chitin/chitosan materials are
that they should be significantly less antigenic than current
shrimp and crab derived chitin materials.
[0007] Mi, F. L., et al., "Fabrication and Characterization of a
Sponge-Like Assymetric Chitosan Membrane as a Wound Dressing",
Biomaterials, 22(2): 165-173 (2001) describes the fabrication and
wound healing function of an asymmetric chitosan membrane produced
by a phase inversion method.
[0008] Chan, M. W., et al., "Comparison of Poly-N-acetyl
Glucosamine (P-GlcNAc) with Absorbable Collagen (Actifoam), and
Fibrin Sealant (Bolheal) for Achieving Hemostasis in a Swine Model
of Splenic Hemorrhage", J. Trauma, Injury, Infection, and Critical
Care, 48(3): 454-458 (2000) describes the testing of
chitin/chitosan hemostatic patches under the moderate blood flow
and oozing typical of the swine spleen capsular stripping test.
[0009] Cole, D. J., et al., "A Pilot Study Evaluating the Efficacy
of a Fully Acetylated poly-N-acetyl glucosamine Membrane
Formulation as a Topical Hemostatic Agent", Surgery 126(3): 510:517
(1999) describes hemostatic agent testing in the swine spleen
capsular stripping test.
[0010] Sandford, Steinnes A., "Biomedical Applications of High
Purity Chitosan" in WATER SOLUBLE POLYMERS, SYNTHESIS, SOLUTION
PROPERTIES AND APPLICATIONS, ACS Series 467, (W. S. Shalaby et al.
Eds. ACS, Washington, D.C. 1991, Ch 28, 431-445). This is a general
review paper describing chitosan use with reference to a chitosan
sponge.
[0011] Mallette, W. G., et al., "Chitosan: A New Hemostat," Annals
of Thoracic Surgery 36(1): 55-58, (1983). See comments concerning
the Malette patents above.
[0012] Olsen, R., et al., In CHITIN AND CHITOSAN, SOURCES,
CHEMISTRY, BIOCHEMISTRY, PHYSICAL PROPERTIES AND APPLICATIONS,
Elsevier Applied Science, London and New York, 1989, 813-828. This
paper concerns the agglutinating efficiency of chitosan.
[0013] Japanese Patent 60142927 covers a chitosan medical band with
improved tack. Japanese patent 63090507A2 describes a water
insoluble and 2% acetic acid insoluble chitosan sponge for external
hemostatic application or for protection of a wound.
[0014] U.S. Pat. No. 5,700,476 describes collagen based
structurally inhomogeneous sponges for wound dressings and/or
implant applications formed by freeze drying techniques employing
at least one pharmacological agent and at least one
substructure.
[0015] U.S. Pat. No. 2,610,625 relates to freeze dried sponge
structures that are highly effective in stopping the flow of blood
or other fluids and which will be absorbed after a time in the
body. This patent describes collagen sponge preparation.
[0016] U.S. Pat. No. 5,836,970 comprises a wound dressing formed of
a blend or mixture of chitosan and alginate.
[0017] Thus, there is a need for improved hemostatic bandages able
to stanch of severe blood flow and that will not fail upon bending
or loading with pressure.
SUMMARY OF THE INVENTION
[0018] The invention is directed to a first-aid/primary
intervention wound dressing for control of severe, life-threatening
bleeding. Presently there are no low cost wound dressings that are
suitable for control of severe life-threatening bleeding. There is
a need for this type of dressing especially in the battlefield,
where typically 50% of all deaths are associated with an inability
to immediately control severe bleeding. The wound dressing of the
invention is capable of substantially stanching the flow of
life-threatening bleeding from a wound by adhering to the wound
site, sealing the wound, accelerating blood clot formation at the
wound site, reinforcing clot formation at the wound site,
preventing bleed out from the wound site, and substantially
prohibiting the flow of blood out of the wound site.
[0019] In one embodiment, a compressed sponge for hemorrhage
control comprising a hydrophilic polymer, wherein the compressed
sponge has a compressed sponge density of about 0.6 to 0.15
g/cm.sup.3 is provided. The hydrophilic polymer may be an alginate,
chitosan, a hydrophilic polyamine, a chitosan derivative,
polylysine, polyethylene imine, xanthan, carrageenan, quaternary
ammonium polymer, chondroitin sulfate, a starch, a modified
cellulosic polymer, a dextran, hyaluronan or combinations thereof.
The starch may be of amylase, amylopectin and a combination of
amylopectin and amylase. Preferably, the hydrophilic polymer is
chitosan. Preferably, the chitosan has a weight average molecular
weight of at least about 100 kDa. More preferably, the chitosan has
a weight average molecular weight of at least about 150 kDa. Most
preferably, the chitosan has a weight average molecular weight of
at least about 300 kDa.
[0020] Preferably, the chitosan has a viscosity at 25.degree. C. in
a 1% solution of acetic acid (AA) with spindle LV1 at 30 rpm which
is about 100 centipoise to about 2000 centipoise. More preferably,
the chitosan has viscosity at 25.degree. C. in a 1% solution of
acetic acid (AA) with spindle LV1 at 30 rpm which is about 125
centipoise to about 1000 centipoise. Most preferably, the chitosan
has viscosity at 25.degree. C. in a 1% solution of acetic acid (AA)
with spindle LV1 at 30 rpm which is about 150 centipoise to about
500 centipoise.
[0021] The compressed sponge may further comprise an active
ingredient. The active ingredient may include, but is not limited
to, calcium, thrombin, factor VIIa, factor XIII, thromboxane A2,
prostaglandin-2a, epidermal growth factor, platelet derived growth
factor, Von Willebrand factor, tumor necrosis factor (TNF),
TNF-alpha, transforming growth factor (TGF), TGF-alpha, TGF-beta,
insulin like growth factor, fibroblast growth factor, keratinocyte
growth factor, nerve growth factor, penicillin, ampicillin,
methicillin, amoxycillin, clavamox, clavulanic acid, amoxicillin,
aztreonam, imipenem, streptomycin, Kanamycin, Tobramycin,
gentamicin, vancomycin, clindamycin, erythromycin, polymyxin,
bacitracin, amphotericin, nystatin, rifampicin, tetracycline,
doxycycline, chloramphenicol and combinations thereof.
[0022] In another embodiment, a compressed composite sponge for
hemorrhage control comprising a hydrophilic polymer sponge and a
wettable polymer matrix or wettable polymer matrices inside the
sponge and/or at the sponge surface is provided. The hydrophilic
polymer may include alginate, a hydrophilic polyamine, a chitosan
derivative, polylysine, polyethylene imine, xanthan, carrageenan,
quaternary ammonium polymer, chondroitin sulfate, a starch, a
modified cellulosic polymer, a dextran, hyaluronan or combinations
thereof. The starch may be amylase, amylopectin and a combination
of both amylopectin and amylase.
[0023] The wettable polymer may include non-woven mats, woven mats,
molded polymer mesh and low density sponges. The wettable polymer
may include, but is not limited to a chitin, an alginate, a
neutralized chitosan, a re-acetylated chitosan, a poly(glycolic
acid), a poly(lactic acid), a poly(e-caprolactone), a
poly(.beta.-hydroxybutyric acid), a poly(.beta.-hydroxyvaleric
acid), a polydioxanone, a poly(ethylene oxide), a poly(malic acid),
a poly(tartronic acid), a polyphosphazene, a polyethylene, a
polypropylene, a metallocene polymer, a polyurethane, a
polyvinylchloride polymer, a polyester, a polyamide and
combinations thereof. Preferably, the hydrophilic polymer is
chitosan.
[0024] Preferably, the chitosan has a weight average molecular
weight of at least about 100 kDa. More preferably, the chitosan has
a weight average molecular weight of at least about 150 kDa. Most
preferably, the chitosan has a weight average molecular weight of
at least about 300 kDa. Preferably, the chitosan has viscosity at
25.degree. C. in a 1% solution of acetic acid (AA) which is about
100 centipoise to about 2000 centipoise. More preferably, the
chitosan has viscosity at 25.degree. C. in a 1% solution of acetic
acid (AA) which is about 125 centipoise to about 1000 centipoise.
Most preferably, the chitosan has viscosity at 25.degree. C. in a
1% solution of acetic acid (AA) which is about 150 centipoise to
about 500 centipoise.
[0025] The sponge may comprise a textile thread impregnated with a
hydrophilic polymer. The textile thread is impregnated with a
hydrophilic polymer. Preferably, the hydrophilic polymer is
chitosan. The hydrophilic polymer may also include, but is not
limited to an alginate, a hydrophilic polyamine, a chitosan
derivative, polylysine, polyethylene imine, xanthan, carrageenan,
quaternary ammonium polymer, chondroitin sulfate, a starch, a
modified cellulosic polymer, a dextran, hyaluronan or combinations
thereof. The starch may include amylase, amylopectin and a
combination of both amylopectin and amylase.
[0026] The wettable mesh may be a non-woven mesh. Preferably, the
sponge contains pores with pore diameters of about 15 microns to
about 300 microns. More preferably, the sponge contains pores with
pore diameters of about 30 microns to about 250 microns. More
preferably, the sponge contains pores with pore diameters of about
100 microns to about 225 microns. More preferably, the sponge
contains pores with pore diameters of about 125 microns to about
200 microns. Most preferably, the sponge contains pores with pore
diameters of about 150 microns to about 175 microns. Preferably,
the sponge has an available blood contacting surface area per base
surface of the sponge of about 100 cm.sup.2 per cm.sup.2 to about
1000 cm.sup.2 per cm.sup.2. More preferably, the compressed
composite sponge has an available blood contacting surface area per
base surface of the sponge of about 200 cm.sup.2 per cm.sup.2 to
about 800 cm.sup.2 per cm.sup.2. Most preferably, the sponge has an
available blood contacting surface area per base surface of the
sponge of about 300 cm.sup.2 per cm.sup.2 to about 500 cm.sup.2 per
cm.sup.2. Preferably, the available mass of chitosan biomaterial
per wound surface area is about 0.02 g/cm.sup.2 to about 1.0
g/cm.sup.2. More preferably, the available mass of chitosan
biomaterial per wound surface area is about 0.04 g/cm.sup.2 to
about 0.5 g/cm.sup.2. Most preferably, the available mass of
chitosan biomaterial per wound surface area is about 0.06
g/cm.sup.2 to about 0.1 g/cm.sup.2.
[0027] The compressed composite sponge further may comprise a
backing support layer. The backing support layer may be a layer of
polymeric material. The polymeric material may be a synthetic
non-biodegradable material or a naturally occurring biodegradable
polymer. The synthetic biodegradable materials may include
poly(glycolic acid), poly(lactic acid), poly(e-caprolactone),
poly(.beta.-hydroxybutyric acid), poly(.beta.-hydroxyvaleric acid),
polydioxanone, poly(ethylene oxide), poly(malic acid),
poly(tartronic acid), polyphosphazene, copolymers of polyethylene,
copolymers of polypropylene, the copolymers of the monomers used to
synthesize said polymers or combinations thereof. The naturally
occurring polymers may include chitin, algin, a starch, dextran,
collagen, albumen and a combination thereof. The synthetic polymers
may include polyethylene, polypropylene, a metallocene polymer, a
polyurethane, a polyvinylchloride polymer, a polyester, a polyamide
or combinations thereof.
[0028] Preferably, the compressed composite sponge has a degree of
adhesion to the wound site of about 40 kPa to about 500 kPa. More
preferably, the compressed composite sponge has a degree of
adhesion to the wound site of about 60 kPa to about 250 kPa. Most
preferably, the compressed composite sponge has a degree of
adhesion to the wound site of about 100 kPa to about 200 kPa.
[0029] The compressed composite sponge is capable of forming an
adhesive material in combination with blood flowing from said wound
at a wound dressing-blood interface. Preferably, the adhesive
material is a chitosan adhesive material. Preferably, the chitosan
adhesive material has a pH of not more than about 6.3 when the
wound is sealed. More preferably, the chitosan adhesive material
preferably has a pH of not more than about 4.5 when the wound is
sealed. Most preferably, the chitosan adhesive material has a pH of
not more than about 4.0 when the wound is sealed.
[0030] The adhesive material may comprise an acid selected from the
group consisting of acetic acid, formic acid, lactic acid, ascorbic
acid, hydrochloric acid and citric acid. Preferably, the compressed
composite sponge has a thickness that is not less than about 3.0 mm
and not more than about 8 mm. More preferably, the compressed
composite sponge has a thickness that is not less than about 3.5 mm
and not more than about 7 mm. Most preferably, the compressed
composite sponge has a thickness that is not less than about 4.0 mm
and not more than about 6 mm. Preferably, the compressed composite
sponge has an ultimate tensile stress about 0.1 Mpa to about 10
MPa. More preferably, the compressed composite sponge has an
ultimate tensile stress of about 0.15 MPa to about 0.8 MPa. Most
preferably, the compressed composite sponge has an ultimate tensile
stress of about 0.25 MPa to about 0.5 MPa.
[0031] Preferably, the compressed composite sponge has an ultimate
elongation of about 5%. More preferably, the compressed composite
sponge has an ultimate elongation of about 10%. Most preferably,
the compressed composite sponge has an ultimate elongation of about
15%.
[0032] In another embodiment, a process for preparing a compressed
sponge for hemorrhage control comprising (a) freezing/freeze drying
preparation of a low density sponge; and (b) compressing the low
density sponge at a preferred rate of about 10 mm per minute and at
a preferred controlled temperature of 80.degree. C. thereby
obtaining a compressed sponge with a density of about 0.1 to about
0.2 g/cm.sup.3, is provided.
[0033] In another embodiment a process for preparing a compressed
sponge for hemorrhage control comprising (a) preparation of a low
density sponge by methods other than freezing/freeze drying
preparation of a low density sponge; and (b) compressing the
subsequent low density sponge at a rate of about 10 mm per minute
and at a preferred controlled temperature of about 80.degree. C.
thereby obtaining a compressed sponge with a density of about 0.1
to about 0.2 g/cm.sup.3, is provided. Preferably, the low density
sponge has a density of about 0.01 g/cm.sup.3 to about 0.035
g/cm.sup.3. Preferably, the compressed sponge has a density of
about 0.1 g/cm.sup.3 to about 0.15 g/cm.sup.3.
[0034] In another embodiment, a process for preparing a compressed
composite sponge for hemorrhage control comprising a) degassing
chitosan biomaterial solution by heating the chitosan biomaterial
solution and applying a vacuum thereto; b) freezing the chitosan
biomaterial solution; c) removing water from within frozen chitosan
biomaterial without damaging the structural integrity of the frozen
chitosan biomaterial so that the water in the chitosan biomaterial
passes from a solid phase into a gas phase; d) compressing the
chitosan biomaterial at a preferred rate of about 10 mm per minute
thereby obtaining a compressed sponge with a density of about 0.1
to about 0.2 g/cm.sup.3; and e) baking the compressed chitosan
sponge at 80.degree. C. for 30 minutes. Preferably, the temperature
is gradually lowered over a predetermined period of time during the
freezing of the chitosan biomaterial of step (b).
[0035] Preferably, the temperature of step (b) is a final freezing
temperature of not more than about -25.degree. C. More preferably,
the process of step (by involves a final freezing temperature of
not more than about -35.degree. C. Most preferably, the temperature
of step (b) is a final freezing temperature of not more than about
-45.degree. C. The water removal may be performed by freeze-drying
the frozen chitosan biomaterial. The process may further comprise a
step of adding argon, nitrogen and helium back into the degassed
chitosan solution before the freezing.
[0036] The compressed sponge may be sterilized. Preferably, the
compressed sponge is sterilized by gamma irradiation.
[0037] In another embodiment, a method of preventing severe
bleeding in a subject comprising administering a compressed sponge
or a compressed composite sponge is provided. Preferably, the
subject is a mammal. More preferably, the mammal is human.
Preferably, the subject is suffering from severe bleeding such that
about 30-40% total blood volume loss would result within 20 to 30
minutes if the bleeding was left uncontrolled. Preferably, the
compressed sponge or compressed composite sponge is applied with
about 60 to 80 kPa pressure directly over the bleeding injury and
held in place for 3 to 5 minutes before releasing, packing and
wrapping.
[0038] In another embodiment, a bandage kit for treating severe
bleeding comprising a compressed sponge or a composite compressed
sponge, gauze rolls for packing and an Ace bandage for wrapping a
wound is provided.
[0039] In another embodiment, a process for mechanical mating and
meshing of the compressed or composite compressed sponges
comprising pressing tissue contacting sides of the sponge against a
macrotextured surface is provided. The macrotextured surface may
include surfaces prepared by chemical etching, surfaces prepared by
ion beam surface ablation, surfaces prepared by mechanical cutting
and surfaces prepared by laser ablation.
[0040] In another embodiment, a process for improving the
mechanical traction of the compressed or compressed composite
sponges comprising pressing tissue contacting sides of the sponge
against a macrotextured surface is provided. Preferably, the
macrotextured surface is selected from the group consisting of
surfaces prepared by chemical etching, and surfaces prepared by
particle blasting techniques.
[0041] In another embodiment, a process for limiting or stopping
the formation of coarse crust on the surface of the composite or
compressed composite sponges comprising covering the surface of the
sponge with a polymer film, a polymer plate, an elevated plastic
plate or a moisture impermeable, breathable membrane film is
provided.
[0042] In another embodiment, a low density sponge, wherein the
sponge is formed by compressing a sponge with an initial density of
about less than 0.05 g/cm.sup.3 until the sponge reaches a density
of about less than 0.08 g/cm.sup.3. The sponge can be formed by a
process other than freezing or freeze drying. Preferably, the
sponge is formed using a method selected from the group consisting
of a phase inversion process, sponges prepared by covalent binding
of active components to preformed matrices, and foaming
techniques.
[0043] In another embodiment, the compressed sponge and compressed
composite sponge may further comprise at least one additional
hydrophilic polymer. The additional hydrophilic polymer may
include, but is not limited to, alginate, chitosan, a hydrophilic
polyamine, a chitosan derivative, polylysine, polyethylene imine,
xanthan, carrageenan, quaternary ammonium polymer, chondroitin
sulfate, a starch, a modified cellulosic polymer, a dextran,
hyaluronan or combinations thereof. The starch may include, but is
not limited to, amylase, amylopectin and a combination of
amylopectin and amylase. Preferably, the hydrophilic polymer is
chitosan.
[0044] An another embodiment provided for is, a compressed sponge
for hemorrhage control comprising a hydrophilic polymer, wherein
the compressed sponge has a compressed sponge density of about 0.6
to 0.15 g/cm.sup.3 the hydrophobic polymer may be a is polyacrylic
acid. Preferably, the compressed sponge may further comprise an
active ingredient. The active ingredient may include, but is not
limited to, calcium, thrombin, factor VIIa, factor XIII,
thromboxane A2, prostaglandin-2a, epidermal growth factor, platelet
derived growth factor, Von Willebrand factor, tumor necrosis factor
(TNF), TNF-alpha, transforming growth factor (TGF), TGF-alpha,
TGF-beta, insulin like growth factor, fibroblast growth factor,
keratinocyte growth factor, nerve growth factor, penicillin,
ampicillin, methicillin, amoxycillin, clavamox, clavulanic acid,
amoxicillin, aztreonam, imipenem, streptomycin, Kanamycin,
Tobramycin, gentamicin, vancomycin, clindamycin, erythromycin,
polymyxin, bacitracin, amphotericin, nystatin, rifampicin,
tetracycline, doxycycline, chloramphenicol or combinations
thereof.
[0045] In another embodiment, a compressed composite sponge for
hemorrhage control comprising a hydrophilic polymer sponge and a
wettable polymer matrix or wettable polymer matrices inside the
sponge and/or at the sponge surface; wherein the hydrophobic
polymer is polyacrylic acid is provided. The wettable polymer
matrices may include non-woven mats, woven mats, molded polymer
mesh and low density sponges. The wettable polymer matrix may
include a chitin, an alginate, a neutralized chitosan, a
re-acetylated chitosan, a poly(glycolic acid), a poly(lactic acid),
a poly(e-caprolactone), a poly(.beta.-hydroxybutyric acid), a
poly(.beta.-hydroxyvaleric acid), a polydioxanone, a poly(ethylene
oxide), a poly(malic acid), a poly(tartronic acid), a
polyphosphazene, a polyethylene, a polypropylene, a metallocene
polymer, a polyurethane, a polyvinylchloride polymer, a polyester,
a polyamide or combinations thereof.
[0046] The sponge may comprise a textile thread impregnated with a
hydrophilic polymer. Preferably, the textile thread is impregnated
with a hydrophilic polymer, wherein the hydrophobic polymer is
polyacrylic acid. Preferably, the wettable polymer matrice is a
non-woven mesh.
[0047] Preferably, the sponge contains pores with pore diameters of
about 15 microns to about 300 microns. More preferably, the sponge
contains pores with pore diameters of about 30 microns to about 250
microns. More preferably, the sponge contains pores with pore
diameters of about 100 microns to about 225 microns. More
preferably, the sponge contains pores with pore diameters of about
125 microns to about 200 microns. Most preferably, the sponge
contains pores with pore diameters of about 150 microns to about
175 microns. Preferably, the sponge has an available blood
contacting surface area per base surface of the sponge of about 100
cm.sup.2 per cm.sup.2 to 1000 cm.sup.2 per cm.sup.2. More
preferably, the sponge has an available blood contacting surface
area per base surface of the sponge of about 200 cm.sup.2 per
cm.sup.2 to 800 cm.sup.2 per cm.sup.2. Most preferably, the sponge
has an available blood contacting surface area per base surface of
the sponge of about 300 cm.sup.2 per cm.sup.2 to about 500 cm.sup.2
per cm.sup.2.
[0048] The compressed composite sponge may further comprise a
backing support layer. Preferably, the backing support layer may be
a layer of polymeric material. Preferably, the polymeric material
is a synthetic non-biodegradable material or a naturally occurring
biodegradable polymer. The synthetic biodegradable materials may
include, but is not limited to, poly(glycolic acid), poly(lactic
acid), poly(e-caprolactone), poly(.beta.-hydroxybutyric acid),
poly(.beta.-hydroxyvaleric acid), polydioxanone, poly(ethylene
oxide), poly(malic acid), poly(tartronic acid), polyphosphazene,
copolymers of polyethylene, copolymers of polypropylene, the
copolymers of the monomers used to synthesize said polymers or
combinations thereof. The naturally occurring polymers may include,
but are not limited to, chitin, algin, a starch, dextran, collagen,
albumen, or combinations thereof. The synthetic polymers may
include, but are not limited to, polyethylene, polypropylene, a
metallocene polymer, a polyurethane, a polyvinylchloride polymer, a
polyester, a polyamide or combinations thereof.
[0049] Preferably, the compressed composite sponge has a degree of
adhesion to the wound site of at about 40 kPa to 500 kPa. More
preferably, the compressed composite sponge has a degree of
adhesion to the wound site of about 60 kPa to 250 kPa. Most
preferably, the compressed composite sponge has a degree of
adhesion to the wound site of about 100 kPa to 200 kPa.
[0050] The compressed composite sponge may be capable of forming an
adhesive material in combination with blood flowing from said wound
at a wound dressing-blood interface. Preferably, the adhesive
material preferably has a pH of not less than about 5.5 when the
wound is sealed. More preferably, the adhesive material preferably
has a pH of not more than about 6.5 when the wound is sealed. Most
preferably, the adhesive material preferably has a pH of not more
than about 7.5 when the wound is sealed. Preferably, the adhesive
material comprises an acid selected from the group consisting of
acetic acid, formic acid, lactic acid, ascorbic acid, hydrochloric
acid, and citric acid. Preferably, the compressed composite sponge
has a thickness that is not less than about 3.0 mm and not more
than about 8 mm. More preferably, the compressed composite sponge
has a thickness that is not less than about 3.5 mm and not more
than about 7 mm. Most preferably, the compressed composite sponge
has a thickness that is not less than about 4.0 mm and not more
than about 6 mm. Preferably, the compressed composite sponge has an
ultimate tensile stress about 0.1 MPa to about 10 MPa. More
preferably, the compressed composite sponge has an ultimate tensile
stress of about 0.15 MPa to about 0.8 MPa. Most preferably, the
compressed composite sponge has an ultimate tensile stress of about
0.25 MPa to about 0.5 MPa.
[0051] Preferably, the compressed composite sponge has an ultimate
elongation of about 5%. More preferably, the compressed composite
sponge has an ultimate elongation of about 10%. Most preferably,
the compressed composite sponge has an ultimate elongation of about
15%.
[0052] In another embodiment, a process for preparing a compressed
sponge of claim 1 for hemorrhage control comprising the steps of
(a) freezing/freeze drying preparation of a low density sponge; and
(b) compressing the low density sponge at a preferred rate of 10 mm
per minute and at a preferred controlled temperature of 80.degree.
C. thereby obtaining a compressed sponge with a density of about
0.1 to about 0.2 g/cm.sup.3 is provided.
[0053] In another embodiment, a process for preparing a compressed
sponge for hemorrhage control comprising the steps of (a) preparing
a low density sponge by methods other than freezing/freeze drying
preparation of a low density sponge; and (b) compressing the
subsequent low density sponge at a rate of 10 mm per minute and at
a preferred controlled temperature of 80.degree. C. thereby
obtaining a compressed sponge with a density of about 0.1 to about
0.2 g/cm.sup.3 is provided. Preferably, the low density sponge has
a density of about 0.01 g/cm.sup.3 to about 0.035 g/cm.sup.3.
Preferably, the compressed sponge has a density of about 0.1
g/cm.sup.3 to about 0.15 g/cm.sup.3.
[0054] In another embodiment, a process for preparing a compressed
composite sponge for hemorrhage control comprising a) degassing
biomaterial solution by heating the biomaterial solution and
applying a vacuum thereto; b) freezing the biomaterial solution; c)
removing water from within frozen biomaterial without damaging the
structural integrity of the frozen biomaterial so that the water in
the biomaterial passes from a solid phase into a gas phase; d)
compressing the biomaterial at a preferred rate of about 10 mm per
minute thereby obtaining a compressed sponge with a density of
about 0.1 to about 0.2 g/cm.sup.3; and e) baking a compressed
sponge at 80.degree. C. for 30 minutes is provided. Preferably, the
temperature is gradually lowered over a predetermined period of
time during the freezing of the biomaterial of step (b).
Preferably, the temperature of step (b) is a final freezing
temperature of not more than about -5.degree. C. More preferably,
the temperature of step (b) is a final freezing temperature of not
more than about -35.degree. C. Most preferably, the temperature of
step (b) is a final freezing temperature of not more than about
-25.degree. C. Preferably, the water removal is performed by
freeze-drying the frozen biomaterial. The process may further
comprise a step of adding argon, nitrogen and helium back into the
degassed chitosan solution before the freezing. The sponge may be
compressed sponge is sterilized. Preferably, the compressed sponge
is sterilized by gamma irradiation.
[0055] In another embodiment, a method of preventing severe
bleeding in a subject comprising administering a compressed sponge
or a compressed composite sponge is provided. Preferably, the
subject is a mammal. More preferably, the mammal is human.
Preferably, the subject is suffering from severe bleeding such that
about 30-40% total blood volume loss would result within 20 to 30
minutes if the bleeding were left uncontrolled. Preferably, the
compressed sponge or compressed composite sponge is applied with
about 60 to 80 kPa pressure directly over the bleeding injury and
held in place for 3 to 5 minutes before releasing, packing and
wrapping the wound.
[0056] In another embodiment, a method is provided for preventing
severe bleeding in a subject comprising administering a compressed
sponge or a compressed composite sponge. Preferably, the subject is
a mammal. More preferably, the mammal is human. Preferably, the
subject is suffering from severe bleeding such that about 30-40%
total blood volume loss would result within 20 to 30 minutes if the
bleeding were left uncontrolled. Preferably, the compressed sponge
or compressed composite sponge is applied with about 60 to 80 kPa
pressure directly over the bleeding injury and held in place for 3
to 5 minutes before releasing, packing and wrapping the wound.
[0057] In another embodiment, a bandage kit for treating severe
bleeding comprising a compressed sponge or a composite compressed
sponge, gauze rolls for packing and an Ace bandage for wrapping a
wound is provided.
[0058] In another embodiment, a process for mechanical mating and
meshing of the compressed or composite compressed sponges
comprising pressing tissue contacting sides of the sponge against a
macrotextured surface is provided. The macrotextured surface may
include surfaces prepared by chemical etching, surfaces prepared by
ion beam surface ablation, surfaces prepared by mechanical cutting,
and surfaces prepared by laser ablation.
[0059] In another embodiment, a process for improving the
mechanical traction of the compressed or compressed composite
sponges comprising pressing tissue contacting sides of the sponge
against a macrotextured surface is provided. Preferably, the
macrotextured surface is selected from the group consisting of
surfaces prepared by chemical etching, and surfaces prepared by
particle blasting techniques.
[0060] In another embodiment, a process for limiting or stopping
the formation of coarse crust on the surface of the composite or
compressed composite sponges comprising covering the surface of the
sponge with a polymer film, a polymer plate, an elevated plastic
plate or a moisture impermeable, breathable membrane film is
provided.
[0061] In another embodiment, a low density sponge, wherein the
sponge is formed by compressing a sponge with a density of about
less than 0.05 g/cm.sup.3 until is reaches a density of about less
than 0.08 g/cm.sup.3, and wherein the sponge is formed by a process
other than freezing or freeze drying is provided. Preferably, the
sponge is formed using a method selected from the group consisting
of a phase inversion process, sponges prepared by covalent binding
of active components to preformed matrices and foaming
techniques.
[0062] In another embodiment, a compressed sponge and compressed
composite sponge, wherein the sponges further comprise a
hydrophilic polymer in combination with the polyacrylic acid is
provided. The hydrophilic polymer may include, but is not limited
to, alginate, chitosan, a hydrophilic polyamine, a chitosan
derivative, polylysine, polyethylene imine, xanthan, carrageenan,
quaternary ammonium polymer, chondroitin sulfate, a starch, a
modified cellulosic polymer, a dextran, hyaluronan or combinations
thereof. The starch may include amylase, amylopectin and a
combination of amylopectin and amylase. Preferably, the hydrophilic
polymer is chitosan.
DESCRIPTION OF THE DRAWINGS
[0063] FIG. 1 shows a photo-digital image of transverse cross
section through early uncompressed wound dressing.
[0064] FIG. 2 shows a photo-digital image of transverse cross
section through oriented lamella structures in uncompressed wound
dressing.
[0065] FIG. 3 shows a light photomicrograph of interconnected
porous chitosan wound dressing structure sectioned normal to
base.
[0066] FIG. 4 shows a Photograph of chitosan biomaterial wound
dressing after heating and compression.
[0067] FIG. 5 shows a scanning electron photomicrograph of a
typical base surface of compressed chitosan wound dressing. Higher
magnification inset (bar=100 micron).
[0068] FIG. 6 shows a histological stained section through
chitosan/spleen injury site and adjacent splenic surface.
Agglutinated clot response (A) with a mixture of fibrin/platelet
rich blood clot (B) between patch and spleen. The figures
demonstrates very good adhesion between spleen and chitosan.
[0069] FIG. 7 shows a photograph of thoracic aorta injury sealed
with chitosan patch.
[0070] FIG. 8 shows a fixed thoracic aorta demonstrating
perforation injury.
[0071] FIG. 9 shows a stained histological section through thoracic
aorta injury.
[0072] FIG. 10 shows a photograph of in vitro burst pressure
failure in a strongly adherent dressing.
[0073] FIG. 11 shows a histogram of water and blood adsorption
results for gamma irradiated and un-irradiated (i.e., unsterilized)
samples.
[0074] FIG. 12 shows a detailed drawing of typical chitosan sponge
appearance.
[0075] FIG. 13 shows the effect of compression on sponge internal
structure as observed in sectioned typical 2% solution sponge
compressed from 17 mm to 5 mm thick.
[0076] FIG. 14 shows a detailed drawing of single lamella showing
surface crenulations.
[0077] FIG. 15 shows a detailed drawing of a lamella surface.
[0078] FIG. 16 shows scanning electron microscopy (SEM) images of
the crenulated structure protruding to the top surface of the
lamella. FIGS. 16(a)-16(g) shows the crenulations at various
magnifications.
[0079] FIG. 17 shows a light microscope image with side lighting of
single lamella removed from near the base of a chitosan sponge
using micro-tweezers. Fine crenulated structure can be seen
protruding normal to the top surface of the lamella.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0080] A. Compressed Sponges and Compressed Composite Sponges
[0081] The invention is directed to a first-aid/primary
intervention wound dressing for control of severe, life-threatening
bleeding. Such bleeding can be fatal in ballistic injuries and
severe arterial lacerations. There is an urgent need for this type
of dressing especially in the battlefield, where typically 50% of
all deaths are associated with an inability to immediately control
severe bleeding.
[0082] An advanced wound dressing for control of severe,
life-threatening bleeding should preferably have the following
properties:
[0083] i) easily and quickly applied in one step after removal from
package;
[0084] ii) rapid and strong blood clotting;
[0085] iii) rapid and strong tissue adhesion;
[0086] iv) strong internal cohesive properties;
[0087] v) rapid and strong wound sealing;
[0088] vi) resistant to dissolution under strong blood flow;
[0089] vii) good compliance with the injury;
[0090] viii) initial good mechanical seating of bandage on tissue
to stop slipping by controlled tissue contacting surface texture;
and
[0091] ix) ability to be treated roughly without compromising
efficacy.
[0092] To this end, the invention is directed to advanced
hemorrhage control wound dressings, and methods of using and
producing such wound dressings. The kind of severe,
life-threatening bleeding contemplated by this invention is
typically of the type not capable of being stanched when a
conventional gauze wound dressing is applied with conventional
pressure to the subject wound. Alternatively, the nature of the
severe, life-threatening bleeding is such that it is not stanched
when a conventional gauze wound dressing is applied with
conventional pressure to the wound and, if not controlled by other
means, would result in the person lapsing into a state of
hypotension. Stated another way, the severe, life-threatening
bleeding is generally not capable of being stanched when a
conventional gauze wound dressing is applied with conventional
pressure to the wound and would result in the systolic blood
pressure of the person dropping to a level of less than about 90 mm
Hg.
[0093] The severe, life-threatening bleeding can also be described
as a steady high flow of blood of more than about 90 mL of blood
loss per minute, such that in about 20 minutes of bleeding a volume
of more than about 40% of total blood from a 70 kg human male would
be lost, and the blood volume loss would substantially reduce the
likelihood of survival of the person. If this type of bleeding was
not stopped within 5-10 minutes, an injured person may lapse into a
hypotensive condition, such that arterial blood pressure drops to
less than 60 mm Hg. In many cases, the severe bleeding is caused by
a ballistic projectile injury or a sharp perforation injury or a
blunt traumatic injury. In other cases, the severe bleeding is
caused by coagulopathy or internal trauma or surgical trauma, motor
vehicle trauma, farming accidents, and the like.
[0094] The wound dressing of the invention is capable of stanching
said severe bleeding which is caused by a substantial arterial
wound or a substantial venous wound having a blood flow rate of at
least about 90 mL/minute, and adhering to the wound site by the
application of direct pressure to the wound dressing for a period
of time of not more than about five minutes. The wound dressing
also acts quickly to seal the wound, and facilitates substantial
clotting and agglutinating of the severe bleeding from the wound
site, and stanches the severe bleeding with the temporary
application of direct pressure to the wound dressing. The wound
dressing has a high resistance to dissolution in high blood flow,
and has good internal cohesion properties. It has sufficient
flexibility to conform to the injury and toughness to resist rough
handling.
[0095] The subject dressing is formed of a biomaterial for
controlling severe bleeding. Preferably, the biomaterial comprises
a non-mammalian material. Preferably, the non-mammalian material is
poly [.beta.-(1.fwdarw.4)-2-amino-2-deoxy-D-glucopyranose], more
commonly referred to as chitosan.
[0096] The wound dressing is formed into a sponge-like or woven
configuration via the use of an intermediate structure or form
producing steps. The biomaterial comprises an interconnected open
porous structure, and/or an oriented open lamella structure, and/or
an open tubular structure, and/or an open honeycomb structure,
and/or a filamentous structure. The wound dressing has
interconnected free-space domains or pores with pore of about 15
microns to about 300 microns; about 30 microns to about 250
microns; about 100 microns to about 225 microns; about 125 microns
to about 200 microns; and most preferably about 150 microns to
about 175 microns. The wound dressing has an available blood
contacting surface area per base surface of said wound dressing of
preferably at least about 100 cm.sup.2 per cm.sup.2, more
preferably at least about 200 cm.sup.2 per cm.sup.2, and most
preferably at least about 300 cm.sup.2 per cm.sup.2. The available
mass of chitosan biomaterial per wound surface area is preferably
about 0.02 g/cm.sup.2 to about 1.0 g/cm.sup.2; more preferably, the
available mass of chitosan biomaterial per wound surface area is
about 0.04 g/cm.sup.2 to about 0.5 g/cm.sup.2; and most preferably,
the available mass of chitosan biomaterial per wound surface area
is about 0.06 g/cm.sup.2 to about 0.1 g/cm.sup.2.
[0097] By "per base surface" is meant, for example, that if 1
cm.times.1 cm of the base surface is taken which is generally
contacting the blood, then one would expect blood to see at least
100 cm.sup.2 of chitosan surface area because of the open sponge
structure.
[0098] Sponges may be prepared by processes including, but not
limited to, phase inversion processes, freezing, freeze drying,
covalent binding of active components to preformed matrices and
foaming techniques.
[0099] Furthermore, the wound dressing has a mean rate of
dissolution per base surface area of said wound dressing when
adhered to said wound site, at a temperature of about 37.degree.
C., of preferably not more than about 0.008 grams per minute per
cm.sup.2, more preferably not more than about 0.005 grams per
minute per cm.sup.2, and most preferably not more than about 0.002
grams per minute per cm.sup.2.
[0100] The subject wound dressing preferably has a density of at
least about 0.05 g/cm.sup.3, more preferably at least about 0.07
g/cm.sup.3, and most preferably at least about 0.11 g/cm.sup.3. It
can have a compression loading preferably to a compression density
at least about 0.05 g/cm.sup.3, more preferably at least about 0.07
g/cm.sup.3, most preferably at least about 0.095 g/cm.sup.3, and
preferably of not more than about 0.2 g/cm.sup.3.
[0101] The wound dressing of the invention typically contains
chitosan with number average molecular weight of at least about 50
kDa, preferably at least about 75 kDa, more preferably at least
about 100 kDa, and most preferably at least about 150 kDa
(molecular weights determined by Gel Permeation Chromatography
relative to polyethylene glycol standards in pH 5.5, 0.01 M sodium
acetate). Preferably, the chitosan adhesive material has a pH of
not more than about 6.3 when the wound is sealed. More preferably,
the chitosan adhesive material preferably has a pH of not more than
about 4.5 when the wound is sealed. Most preferably, the chitosan
adhesive material has a pH of not more than about 4.0 when the
wound is sealed.
[0102] With regard to dressings where the hydrophilic polymer is
polyacrylic acid, preferably the adhesive material has a pH of not
less than about 5.5 when the wound is sealed. More preferably, the
adhesive material preferably has a pH of not less than about 6.5
when the wound is sealed. Most preferably, the chitosan adhesive
material has a pH of not less than about 7.5 when the wound is
sealed.
[0103] The chitosan also preferably has a weight average molecular
weight of at least about 100 kDa, more preferably at least about
150 kDa, and most preferably at least about 300 kDa (molecular
weights determined by Gel Permeation Chromatography relative to
polyethylene glycol standards in pH 5.5, 0.01 M sodium acetate).
The chitosan in the wound dressing also has a Brookfield LV DV-II+
viscosity at 25.degree. C. in a 1% solution of acetic acid (AA)
with a spindle at about 30 rpm which is preferably about 100
centipoise to about 2000 centipoise, more preferably about 125
centipoise to about 1000 centipoise, and most preferably about 150
centipoise to 500 centipoise. The spindle is preferably spindle
LV1, LV2, LV3 or LV4. The molecular weights and viscosities
referred to above are in respect to substantially pure chitosan
wound dressings and wound dressings formed with an adsorbed surface
layer of chitosan. In the case of a wound dressing containing a
covalently bound surface layer of chitosan, then lower viscosities
and molecular weights of chitosan may be preferred.
[0104] The wound dressing of the present invention can comprise
cationic chitosan salts for promoting tissue adhesion and tissue
sealing. Preferably, the cationic chitosan salts may include, but
are not limited to, chitosan formate, chitosan acetate, chitosan
lactate, chitosan chloride, chitosan ascorbate and chitosan
citrate. The chitosan has a degree of deacetylation, which is
typically at least about 70%, preferably at least about 75%, more
preferably at least about 80%, most preferably at least about
85%.
[0105] It is preferable to compact a low density sponge
(density<0.03 g/cm.sup.3 solid), rather than to compact a medium
density sponge (0.1 g/cm.sup.3>density>0.5 g/cm.sup.3 by
volume solid) or a medium density sponge, already at the preferred
density, to its optimal density of close to 0.15 g/cm.sup.3. This
is because the process of sponge formation in low density sponge
results in significantly thinner wall thicknesses between sponge
pores compared to wall thicknesses in medium and higher density
sponges. Also these higher density sponges often have a more
interconnected structure which increases sponge stiffness, and
decreases resistance to cracking. The multiple thin walls in the
low density sponges, when compressed to higher densities allow for
more flexible and tougher sponges than medium and higher density
sponges which are produced with more interconnected structure as
well as thicker and hence stiffer cell walls.
[0106] Sponge densification may be accomplished ether by
unidirectional or bi-directional application of a controlled
compression rate at a fixed temperature. A preferred sponge
densification is accomplished by unidirectional compression at
80.degree. C. and with sponge moisture content between about 2% and
5% w/w. As an example of uni-axial compression, a 10.0 cm (x
direction),.times.10.0 cm (y direction).times.1.70 cm (z direction)
was compressed at 10 mm/min in the z direction between flat,
horizontally oriented (xy plain), 63.5 cm.times.50.8 cm aluminum
platens in a Geo Knight 394-TS shuttle press at 40 psi. Compression
rate was controlled by pressure setting and use of a Parker SPF200B
needle valve.
[0107] The final sponge thickness of 0.55 cm was controlled by use
of at least two spacer bars 50 cm.times.2 cm.times.0.55 cm. The
initial density of the sponge was 0.033 g/cm.sup.3. The density of
the sponge after pressing was 0.10 g/cm.sup.3. Other spacer
controls such as 0.15 cm, 0.35 cm and 0.45 cm height have been used
to achieve sponges of 0.375 g/cm.sup.3, 0.16 g/cm.sup.3 and 0.125
g/cm.sup.3 respectively. Bidirectional compression (platen
compression in z and x or y directions) can be carried out to
reduce a 5 cm.times.5 cm.times.1.7 cm sponge to a 2.5 cm.times.2.5
cm.times.0.55 cm sponge. Complex shapes may be compressed using
vacuum bagging techniques where a closed plastic film is wrapped
over the surface of the sponge and air removed from inside the
sponge and plastic film jacket to a controlled level by application
of a vacuum. A heated roller press may also be used to compress
sponge ribbon and other sponge profiles. It is preferred that such
sponge ribbons and profiles are reinforced with an internal
composite mesh if they are pressed using a roller press. A
preferred embodiment of the compression of continuous composite
sponge filaments is that the filament is drawn through a heated
Teflon.TM. coated rod die (80.degree. C.), with a controlled taper
at the entrance from close to 2.5 mm diameter to 0.67 mm diameter
at full compression.
[0108] Conditions of controlled moisture, heat application and
compression rate are chosen to optimize ductile compaction while
minimizing brittle collapse of the sponge. Brittle collapse of the
sponge results in loss of sponge mechanical integrity by cracking.
Optimal sponge compaction to fine interconnected zones is best
accomplished in sponges with uniform interconnected sphere-like
pores (e.g. dodecahedral). The uncompressed sponge pore size is
optimal between 30 and 120 microns with polymer wall thickness from
1 to 20 microns. In the case of sponges with lamella or
honeycomb-like structure, it is best that the structure is
uniformly oriented near 30 to 40 degrees from the normal direction
of uniaxial compression. It is possible to obtain such uniform
structure during freezing by application of a sheer stress normal
to the direction of the thermal gradient. Such sheers are
accomplished by application of uniform loading in the direction of
the freezing and with reduced loading in the normal direction to
the heat loss.
[0109] Near vertical structures are less readily compressed without
brittle fracture and random channel formation. In fact, course
vertical structures that originate from top surface ice nucleation,
during freezing in an open mold, lead to a vertical crust layer in
the sponge that does not readily compress, causes stiffness in the
sponge and rapidly dissolves when contacting blood or aqueous
solutions. Also horizontal structures are undesirable since they
compress elastically in the bulk and with loss of pore
interconnectivity at the surfaces.
[0110] Also in the lamella-type or honeycomb-like sponges, it is
desired that the wall structure have a crenulated or ciliated
surface. Such surfaces on lamella or honeycomb walls are achieved
under specific conditions during the freezing controlled phase
separation of ice and hydrophilic polymer. Usually the crenulations
or cilia are orthogonal to the lamella or honeycomb surface
protruding from the surface as thin walls, "teeth", "combs" or
columns 3 to 10 microns and 3-10 microns in length in the case of
crenulations or 2-3 microns in diameter in the case of cilia. They
are distributed on the lamella or honeycomb wall, often with
maze-like regularity: one wall adjacent another at 5-10 microns
separations but always apart. The extent of the crenulations
appears to be controlled by the molecular weight of the polymer,
its molecular weight distribution, the extent of elongated rod-like
solution properties prior to and during phase separation and the
cooling regime. On densification, these crenulations act to
maintain pore connections by buttressing a desired controlled
spacing of lamella to at least about 5 to 10 microns as lamella are
compressed against each other.
[0111] Surface cilia and crenulations also play an important role
in adhesion by assisting in mechanical anchoring and mating of
surfaces. Hence the surface texture of crenulated/ciliated
structures is best preserved during densification. This can be
achieved by compression of the positive sponge surface into a
negative base surface. Ideally the texture of this base surface is
the release negative of the crenulated/ciliated surface. Thus, with
minimum application of load, the first surface would exactly key
into the second surface providing for maximum surface area contact
between the two surfaces. Also on removing the first surface from
the second, there necessarily would be good release of surfaces
without significant surface damage or loss. As well as this
micro-keying of surfaces during pressing, it is also possible to
create macro-patterning in the sponge surface by application of a
designated template surface against which the sponge is pressed
during the compression step. Such patterning may include non-slip
patterns that would assist with primary hemostatic bandage
application to a tissue injury.
[0112] Rectangular, cylindrical, spherical, complex forms and
composite forms may be compressed to optimal densities for control
of hemorrhaging. Sponges can be prepared with composite forms. A
typical rectangular composite form could include an insoluble, but
wet-able, non-woven or woven mesh within the sponge. This would
typically be done by carrying out the sponge forming phase
separation process with the mesh present within the pre-sponge
solution. A non-woven mesh material is preferred since this
material is more compatible with the sponge compression process and
is less likely to cause tearing in the sponge during densification.
Another embodiment is where a low density chitosan sponge from a
0.25% to 1% chitosan solution has been formed by freeze/freeze
drying into a chitosan sponge. This sponge is then re-acetylated to
a chitin sponge form by soaking for at least 24 hours in 99% acetic
anhydride at room temperature. This re-acetylated sponge can then
be applied on or in a chitosan mold solution (1% to 2%), the
chitosan solution formed into a sponge by freeze/freeze drying. The
composite chitosan sponge reinforced by the chitin sponge is then
subsequently pressed to an optimal density. Another embodiment of
the composite form is one where a chitosan sponge has been formed,
most preferably by a freeze/freeze drying procedure. This chitosan
sponge is then neutralized by washing in a 0.1 M NaOH solution, and
then rinsed in water to remove residual sodium salts and sodium
hydroxide. The neutralized chitosan sponge (now water and blood
insoluble) is now placed on or within an aqueous solution of
hydrophilic polymer salt solution (pH.gtoreq.7) in a suitable mold.
The mold is placed in a freeze/freeze dryer to produce a
hydrophilic sponge reinforced with neutralized chitosan sponge. The
subsequent composite sponge is then pressed to an appropriate
thickness.
[0113] A highly preferred cylindrical sponge composite form is that
where the sponge is formed within a wetted yarn or textile. The
diameter of the sponge and yarn would typically be 1-2 mm.
Compression of this yarn, normal to its axis, results in a flexible
chitosan impregnated yarn of 0.2 to 0.5 mm in diameter that can be
woven into a strong compliant medical bandage tape for
administering to internal bleeding injuries and injuries requiring
overlaying, and manipulation of multiple lacerated locations to
control the bleeding. Such a tape would be extremely convenient for
layering to wounds of various degrees of severity including those
that are hemorrhagic. The impregnated polymer in the tape would
accelerate local clotting as well as adhere firmly to tissue. A
chitosan impregnated yarn of this type would provide for
accelerated clotting in individuals with compromised normal
platelet clotting such as hemophiliacs and persons in shock.
[0114] The sponges of the invention may be matted and meshed using
mechanical means. Specifically, the side of the sponge that will be
contacting the subjects wound and tissue upon use may be pressed
against a microtexured surface. The microtexured surface may
include, but is not limited to surfaces prepared by mechanical
cutting and surfaces prepared by laser ablation. The mechanical
traction of the sponge may also be improved by pressing the surface
of the sponge that will be in contact with the subjects wound and
tissue upon use against a macrotextured surface. The macrotextured
surface may include, but is not limited to surfaces prepared by
chemical etching, and surfaces prepared by particle blasting
techniques.
[0115] The sponge may comprise a textile thread impregnated with a
hydrophilic polymer. The thread may be any material, synthetic or
natural, which may absorb the hydrophilic polymer. For example, the
thread may be a vegetable based material. Preferably, the thread is
multi-filimented.
[0116] The sponge wound dressing may have a backing support layer
attached to it that provides for and that facilitates improved
handling and mechanical properties. This backing layer can be
attached or bonded to the dressing by direct adhesion with the top
layer of chitosan, or an adhesive such as 3M 9942 acrylate skin
adhesive, or fibrin glue or cyanoacrylate glue can be employed.
This backing support layer is also preferably substantially blood
insoluble. The backing support layer is also preferably
substantially blood impermeable. The backing support layer is also
preferably substantially biodegradable. The backing support layer
is preferably a material, which allows for firm handling of the
bandage during application and non-sticking to hands once bandage
has been applied.
[0117] Preferably, the material, which forms the backing support is
a layer of polymeric material. Examples of preferred backing
materials include low-modulus meshes and/or films and/or weaves of
synthetic and naturally occurring polymers. Synthetic biodegradable
materials may include, but are not limited to, poly(glycolic acid),
poly(lactic acid), poly(e-caprolactone), poly(.beta.-hydroxybutyric
acid), poly(.beta.-hydroxyvaleric acid), polydioxanone,
poly(ethylene oxide), poly(malic acid), poly(tartronic acid),
polyphosphazene, copolymers of polyethylene, copolymers of
polypropylene, and the copolymers of the monomers used to
synthesize the above-mentioned polymers or combinations thereof.
Naturally occurring biodegradable polymers may include, but are not
limited to, chitin, algin, starch, dextran, collagen and albumen.
Non-biodegradable polymers for temporary external wound
applications include polyethylene, polypropylene, metallocene
polymers, polyurethanes, polyvinylchloride polymers, polyesters,
polyamides or combinations thereof.
[0118] The wound dressing of this invention has the degree of
adhesion to the wound site which is preferably at least about 40
kPa, more preferably at least about 60 kPa, and most preferably at
least about 100 kPa. Also, the wound dressing has a thickness that
is preferably not less than about 3.0 mm, more preferably not less
than about 3.5 mm, and most preferably not less than about 4.0 mm,
and preferably not more than about 8.0 mm, more preferably not more
than about 7.0 mm, and most preferably not more than about 6.5
mm.
[0119] The wound dressing (2.5 cm wide) of this invention
preferably has an ultimate tensile breaking load of not less than 1
kg, more preferably at least 1.5 kg and most preferably at least
2.25 kg. This same dressing preferably has an ultimate elongation
of at least 5%, more preferably at least 10% and most preferably at
least 15%. The Young's modulus of this dressing is preferably less
than 10 MPa, more preferably less than 3 MPa and most preferably
less than 1 MPa.
[0120] The wound dressing preferably includes a supplemental
traction surface which is particularly useful for the application
of the wound dressing to a wound site which includes a significant
amount of surface blood. The supplemental traction surface can
comprise at least one outer surface that grips the wound site to
avoid slipping of wound dressing, typically in a direction away
from the wound site, during use. The supplemental traction surface
is preferably in the form of a tread design.
[0121] The subject wound dressing is capable of forming an adhesive
material in combination with blood flowing from said wound at the
wound dressing-blood interface. In this case, the chitosan adhesive
material preferably has a pH of not more than about 5.5, more
preferably not more than about 4.5, most preferably not more than
about 4, when the wound is sealed. Typical acids employed for
purposes of adjusting the pH of the chitosan wound dressing are as
follows: acetic acid, formic acid, lactic acid, ascorbic acid,
hydrochloric acid and citric acid. The mole ratio of acid anion to
glucosamine functional groups in the chitosan cation/anion pair to
adjust the pH to the level described above is preferably about
0.90, more preferably about 0.75, and most preferably about
0.60.
[0122] The wound dressing is capable of being conformed to the
configuration of the wound, for engagingly contacting the wound,
and for facilitating stanching of the flow of the severe
life-threatening bleeding. More particularly, the wound dressing is
introduced into the interstices of the wound. More preferably, the
wound dressing is capable of being conformed into a tubular
configuration. Then, the reconfigured wound dressing is inserted
into the wound.
[0123] This invention also contemplates a method for controlling
severe, life-threatening bleeding from a wound at a wound site of a
person. The method comprises providing a wound dressing formed of a
biomaterial comprising chitosan, adhering said wound dressing to
the wound site and substantially stanching the flow of said severe
life-threatening bleeding from said wound. Preferably, the wound is
sealed and bleed out is prevented from said wound site. Also,
bleeding and the flow of other fluids into and/or out of the said
wound site are preferably prevented. The dressing of the invention
acts to rapidly produce a strong clot at the bleeding site by
agglutinating red blood cells. It can also promote clotting by
accelerating the normal platelet clotting pathway.
[0124] In certain applications, the dissolution rate of the subject
wound dressing has been relatively slow compared to the
agglutination rate, and this balance produces good results, as
agglutination at high rate stops dissolution. This demonstrates the
importance of uniformity of the internal and surface structure of
the wound dressing. If a substantial defect is present in the wound
dressing, such as a channel caused by grain boundaries or minor
cracking, then significant blood flow will channel its way along
the defect and produce a highly undesirable bleed-through
condition, which can flush away the smaller less-viscous
agglutination areas as they form. Also significant blood flow at
pressure over the wafer surface appears to adversely affect wound
adhesion of prior art wound dressing, but not the wound adhesion of
the wound dressing of this invention.
[0125] An important preferred attribute of the wound dressing of
the invention is the means of combining the chitosan with the
blood, while achieving mechanical integrity of the resultant "clot"
and binding of the clot to the surface immediately adjacent to the
injury. The subject wound dressing accelerates blood clot formation
at the wound site, reinforces clot formation at the wound site and
prevents bleed out from the wound site. It also substantially
prevents the flow of blood and other fluids into and/or out of the
wound site.
[0126] The wound dressing of the present invention maintains its
dual capability for clotting and adhesion to a wound site, while
also exhibiting a high level of resilience in an extreme
environment. The outstanding resilience of this wound dressing is
exemplified by the formidable physical properties of the dressing.
The subject wound dressing, unlike prior art products described
previously, also has an outstanding ability to conform to wound
shape while maintaining structural resilience. This structural
resilience allows the wound dressing to assume a preferred shape
after deformation, without any substantial loss of mechanical
properties.
[0127] Preferably, the hemorrhage control dressing of the invention
includes a surface that grips the wound area to substantially avoid
slipping of the dressing during use. Typically, this non-slip
surface of the dressing comprises a traction surface. The subject
hemorrhage control dressing may benefit from having an effective
non-slip surface, such as a traction surface. The subject
hemorrhage control dressing can have a smooth and rough side. The
rougher side is preferably the tissue or bleeding surface side, if
that side also demonstrated better adhesive properties.
[0128] A traction surface may improve a dressing ability to control
rapid arterial bleeding by providing increased stability of surface
contact (better traction) on a well lubricated surface (such as
those surfaces which present in the case of severe bleeding). Such
a traction surface helps to channel blood, without adversely
affecting adhesion kinetics while allowing for a more controlled
and stable tissue contact during the critical period of dressing
application. For example, the tissue side of the bandage may have a
traction surface in the form of a tread design. This tread could
prevent the dressing from undergoing traction loss in a direction
away from the wound when undergoing application to the wound.
[0129] The non-slip surface of the hemorrhage control dressing may
be produced with ridges that are non-connecting or blinded to one
another. Thus, in turn, the channels formed between the ridges
would be fully or partially blinded to one another and thus provide
a controlled connection that would provide for a controlled blood
flow back into or out of the wound area. The controlled blood flow
in the area of dressing application may be maintained by the ridges
or specific types of responsive gates in the hemorrhage control
dressing. Ridges on the bottom of a mold for producing the
hemorrhage control dressing may include depressions of the type
which will permit a non-slip surface, for example, in the form of
traction controls such as ridges or the like, in the subject
dressings.
[0130] Thus, a hemorrhage control dressing may be produced having
at least one non-slip surface, such as a traction surface. Also, a
method of producing such a dressing could be provided. Finally, a
mold to a produce a hemorrhage control dressing may be
fabricated.
[0131] To treat severe hemorrhage in cases where adhesive base and
top surfaces are advantageous, it is possible to design the support
backing so that it may be readily peeled away when adhesion and
clotting are required on both surfaces.
[0132] There are numerous hemorrhage control configurations of the
dressing to address a wide range of possible types of hemorrhagic
wound. It may be necessary to carry several bandages of differing
configurations (for example, in a battlefield situation) so that
the injured persons may be treated by the first responder or even
potentially by injured persons themselves. The dressing of the
invention can tolerate a great deal of physical abuse and still
remain an active hemorrhage control platform.
[0133] The dressing is ideal for treating focal vascular bleeding
as well as small topical wounds. It is also well suited to packing
into complex entry wounds where the bleeding site cannot be easily
compressed.
[0134] Once hemorrhage control is achieved with the current
invention, stabilizing an extremity wound, approximating wound
edges and creating a durable dressing that will prevent
contamination and allow evacuation of the injured for definitive
repair are the main requirements for a civilian and a battlefield
hemorrhage control dressing. One envisioned configuration of the
hemorrhage control dressing is a 10".times.18" dressing with a
flexible, elastic backing that can be tightly attached around an
extremity and secured with a locking tab such as a permanent
adhesive glue via a peel back surface to itself. This configuration
would approximate wound surfaces and add a hemorrhage control
surface without compromising blood flow to the distal extremity,
and may be applied by a first responder or in some instances by the
injured soldier and would be stable under ambulation or extremity
movement during transport. It is envisioned that the bandage would
be removed by cutting it apart with no adverse adhesion to the
wound or skin.
[0135] B. Methods of Making Compressed Sponges and Compressed
Composite Sponges
[0136] A method is provided for producing a wound dressing capable
of controlling severe, life-threatening bleeding from a wound at a
wound site of a person. Such a method comprises the steps of
providing a chitosan biomaterial as described above.
[0137] The structure or form producing steps are typically carried
out from solution and can be accomplished employing techniques such
as freezing (to cause phase separation), non-solvent die extrusion
(to produce a filament), electro-spinning (to produce a filament),
phase inversion and precipitation with a non-solvent (as is
typically used to produce dialysis and filter membranes) or
solution coating onto a preformed sponge-like or woven product. In
the case of freezing, where two or more distinct phases are formed
by freezing (typically water freezing into ice with differentiation
of the chitosan biomaterial into a separate solid phase), another
step is required to remove the frozen solvent (typically ice), and
hence produce the wound dressing without disturbing the frozen
structure. This may be accomplished by a freeze-drying and/or a
freeze substitution step. The filament can be formed into a
non-woven sponge-like mesh by non-woven spinning processes.
Alternately, the filament may be produced into a felted weave by
conventional spinning and weaving processes. Other processes that
may be used to make the said biomaterial sponge-like product
include dissolution of added porogens from a solid chitosan matrix
or boring of material from said matrix.
[0138] Preferably, the chitosan biomaterial is degassed of general
atmospheric gases. Typically, degassing is removing sufficient
residual gas from the chitosan biomaterial so that, on undergoing a
subsequent freezing operation, the gas does not escape and form
unwanted large voids or large trapped gas bubbles in the subject
wound dressing product. The degassing step may be performed by
heating a chitosan biomaterial, typically in the form of a
solution, and then applying a vacuum thereto. For example,
degassing can be performed by heating a chitosan solution to about
60.degree. C. immediately prior to applying vacuum at about 500
mTorr for about 5 minutes while agitating the solution.
[0139] One embodiment of he hydrophilic polymer biomaterial sponge
solution treatment is to add certain gases back into the solution
after initial degassing. Such gases would include but are not
limited to argon, nitrogen and helium. An advantage of this step is
that solutions containing partial pressures of these gases form
micro-voids on freezing. The microvoid is then carried through the
sponge as the ice-front advances. This leaves a well defined and
controlled channel that aids sponge pore interconnectivity.
[0140] Next, the chitosan biomaterial, which is typically in
solution form, is subjected to a freezing step. Freezing is
preferably carried out by cooling the chitosan biomaterial solution
and lowering the solution temperature from room temperature to a
final temperature below the freezing point. In this way, the
preferred structure of the wound-dressing product may be prepared.
The final freezing temperature is preferably not more than about
-10.degree. C., more preferably not more than about -20.degree. C.,
and most preferably not more than about -30.degree. C. Preferably,
the temperature is gradually lowered over a predetermined time
period. For example, the freezing temperature of a chitosan
biomaterial solution can be lowered from room temperature to
-45.degree. C. by application of a constant temperature cooling
ramp of between about -0.4.degree. C./min to about -0.8.degree.
C./min for a period of about 90 minutes to about 160 minutes.
[0141] The frozen chitosan biomaterial may then undergo water
removal from within the interstices of the frozen material. This
water removal step may be achieved without damaging the structural
integrity of the frozen chitosan biomaterial. This may be achieved
without producing a substantial liquid phase, which can disrupt the
structural arrangement of the ultimate wound dressing. Thus, the
chitosan biomaterial passes from a solid frozen phase into a gas
phase without the substantial formation of an intermediate liquid
phase.
[0142] The preferred manner of implementing water removal is by
employing a freeze-drying step. Freeze-drying of the frozen
chitosan biomaterial can be conducted by further freezing the
frozen chitosan biomaterial. Typically, a vacuum is then applied.
Next, the evacuated frozen chitosan material may be heated. Then,
there the heated, evacuated, frozen chitosan material is preferably
dried.
[0143] More specifically, the frozen chitosan biomaterial may be
subjected to subsequent freezing preferably at about -15.degree.
C., more preferably at about -25.degree. C., and most preferably at
about -45.degree. C., for a preferred time period of at least about
1 hour, more preferably at least about 2 hour, and most preferably
at least about 3 hour. This step can be followed by cooling of the
condenser to a temperature of less than about -45.degree. C., more
preferably at about -60.degree. C., and most preferably at about
-85.degree. C. Next, a vacuum in the amount of preferably at most
about 150 mTorr, more preferably at most about 100 mTorr, and most
preferably at least about 50 mTorr, can be applied. Then, the
evacuated frozen chitosan material can be heated preferably at
about -25.degree. C., more preferably at about -15.degree. C., and
most preferably at about -10.degree. C., for a preferred time
period of at least about 1 hour, more preferably at least about 5
hour, and most preferably at least about 10 hour. Finally, drying
can be conducted at preferably at a temperature of about 20.degree.
C., more preferably at about 15.degree. C., and most preferably at
about 10.degree. C., for a preferred time period of at least about
36 hour, more preferably at least about 42 hour, and most
preferably at least about 48 hour.
[0144] Subsequently, the chitosan biomaterial may be compressed,
for example by using heated platens to reduce the thickness and
increase the density of said wound dressing. The compression
temperature is preferably not less than about 60.degree. C., more
preferably it is not less than about 75.degree. C. and not more
than about 85.degree. C. Then, the pressed chitosan biomaterial is
preferably preconditioned by heating same to a temperature of
preferably up to about 75.degree. C., more preferably to a
temperature of up to about 80.degree. C., and most preferably to a
temperature of preferably up to about 85.degree. C. Preconditioning
is typically conducted for a period of time up to about 0.25 hours,
preferably up to about 0.35 hours, more preferably up to about 0.45
hours, and most preferably up to about 0.50 hours, thereby
increasing the adhesion strength and dissolution resistance of said
wound dressing, as previously described above.
[0145] The processed wound dressing may then be subjected to a
sterilization step. The dressing can be sterilized by a number of
methods. For example, a preferred method is by irradiation, such as
by gamma irradiation, which can further enhance the blood
dissolution resistance, the tensile properties and the adhesion
properties of the wound dressing. The irradiation can be conducted
at a level of at least about 5 kGy, more preferably a least about
10 kGy, and most preferably at least about 15 kGy. The sterilized
wound dressing can be subsequently packaged for storage in a heat
sealed pouch purged with an inert gas such as either argon or
nitrogen gas.
[0146] A wound dressing is produced from the chitosan biomaterial,
which is capable of substantially stanching the flow of severe
life-threatening bleeding from a wound by adhering the wound
dressing to the wound site. The wound dressing is preferably sealed
to said wound and prevents bleed out from said wound site by
adhering said wound dressing to said wound site employing clotting
and agglutinating of the severe bleeding. This wound dressing
preferably adheres strongly to the wound site, while clotting and
agglutinating red blood cells from around the wound, so that
pressure need only be employed preferably in the first five minutes
of application. In one form of this invention, the device is
designed to be a temporary dressing that is applied, even by
unskilled practitioners, in order to keep the wounded person alive
until expert medical intervention is possible.
[0147] C. Active Agents Used in Compressed Sponges
[0148] The compressed sponge may further comprise an active
ingredient. The active ingredient may be, but is not limited to,
human serum albumen, calcium, bovine thrombin, human Thrombin
(hThrombin), rhThrombin, factor VIIa, factor XIII, recombinant
Factor XIII (rFactor XIII), thromboxane A2, prostaglandin-2a,
epidermal growth factor, platelet derived growth factor, Von
Willebrand factor, tumor necrosis factor (TNF), TNF-alpha,
transforming growth factor (TGF), TGF-alpha, TGF-beta, insulin like
growth factor, fibroblast growth factor, keratinocyte growth
factor, nerve growth factor, penicillin, ampicillin, methicillin,
amoxycillin, clavamox, clavulanic acid, amoxicillin, aztreonam,
imipenem, streptomycin, Kanamycin, Tobramycin, gentamicin,
vancomycin, clindamycin, erythromycin, polymyxin, bacitracin,
amphotericin, nystatin, rifampicin, tetracycline, doxycycline and
chloramphenicol, or combinations thereof depending on the nature of
the wound or the medical condition of the patient. For example,
wounds received in a military setting may comprise an antibiotic,
an antifungal, and a clotting factor. Cancer patients in surgery
may receive a different combination of active agents.
EXAMPLE 1
Hemorrhage Control Testing
[0149] Table 1 provides a list of the main chitosan materials
acquired for hemorrhage control testing. With the exception of the
Gelfoam.TM.+thrombin, and Surgicel.TM. controls for swine spleen
experiments and the Johnson and Johnson 4".times.4" gauze control
for use in swine aortic perforations, the dressing materials
described here were all chitosan-based.
1TABLE 1 Carbomer Genis Source Protosan (Norway) (USA) Primex
(Norway) (Iceland) Sample Name G213 G113 CL213 CL113 9012-75-4
Chitoclear Batch Number 511-583- 005-370-01 607-783-02 310-490-01
VA-UY992 BN 381 TM 752 TM 751 SO11115-1 01 Bio- Source Crab
&/or Crab &/or Crab &/or Crab &/or Shrimp Shrimp
Shrimp Shrimp Shrimp Shrimp Shrimp Shrimp Shrimp Appearance Fine
white Fine white Fine white Fine white Yellowed Fine off- Fine off-
Fine off- Off-white powder powder powder powder powder + white
white white flake specks powder powder powder Viscosity cps 108 12
133 12 NA NA 109 156 1216 (1% soln) % Dry Matter 93.0 90.3 90.8
93.9 NA NA 97.7 97.6 93 % Protein 0.2 0.2 0.1 0.1 NA NA <0.3%
<0.3% <0.3% % Deacetylation 86 85 84 87 90 89 93 91 90 Low
Metals* Yes Yes Yes Yes Yes Yes Yes Yes Yes Salt Glutamate
Glutamate Chloride Chloride Non salt Non salt Non salt Non salt Non
salt Below accepted limits of lead, mercury, bismuth, antimony,
tin, cadmium, silver, copper and molybdenum. NA = not
available.
[0150] Aqueous solutions (2.00% w/w) were prepared in clean,
sterile, 1 liter Pyrex flasks from Ametek, ultrafiltered (UF) water
and dry chitosan. In the case of the Carbomer, Primex and Genis
chitosan materials, 1.0% or 2.0% w/w of glacial acetic acid
(Aldrich 99.99%) was added to the aqueous mixtures. Dissolution was
achieved by shaking of the flask at 40.degree. C. for 12 to 48
hours. The solutions were degassed by application of vacuum at 500
mTorr at room temperature immediately prior to freezing.
[0151] Wound dressings were prepared from the 2% aqueous solutions
of chitosan that were poured into Teflon.TM.-coated aluminum or
polystyrene molds to at least 1.5 cm deep and frozen in a
-80.degree. C. Revco freezer at -45.degree. C. for 3 hours.
Alternatively, freezing was carried out on the shelves inside a
Virtis Genesis 35EL freeze drier. There was at most 10% shrinkage
in the wound dressings and the final freeze-dried wound dressing
density was near 0.033 g/cm.sup.3. Transverse cross sections of two
types of molded wound dressings are shown in FIGS. 1 & 2
(different freezing rates). The structures observed (FIG. 3) were
affected by the rates of cooling in the bulk solution and at the
different surfaces. Subsequently, structures in the wound dressings
were controlled by formulation, mold (size & shape) and
freezing conditions. Optimal wound dressing structures were those
that were open-porous consisting of uniform interconnected pores of
close to 50 microns in diameter or lamella and hexagonal structures
normal to the plane of cooling. These structures could be
controlled, yielding flexible yet strong wound dressings of large
specific surface areas for highly efficient and rapid blood
coagulation. Typically, the available specific surface area for
such structures was greater than 500 cm.sup.2/g. The scanning
electron photomicrograph in FIG. 5 shows the typical open cell
structure in the base surface of a wound dressing. The wound
dressings were heated in a convection oven at 80.+-.1.degree. C.
for one half hour to optimize the structure and distribution of
acetic acid concentration. It was found that this step was
essential to optimize the adhesive properties of the wound dressing
in a bleeding field (typically adhesion to dermis>40 kPa).
[0152] The wound dressings were immediately compressed from 17 mm
thickness to 5.5.+-.0.5 mm at 80.+-.5.degree. C. under a loading of
close to 50 kPa (from ca. density 0.03.+-.0.005 g/cm.sup.3 to
0.12.+-.0.02 g/cm.sup.3). FIG. 4 shows the appearance of the base
of a typical preferred chitosan wound dressing for hemorrhage
control after heating and compression.
EXAMPLE 2
Preparation and Evaluation of Wound Dressing
[0153] Hemostatic wound dressings were prepared as follows:
[0154] a) Dry chitosan powder or flake with degree of deactylation
above 85%, less than 26 ppm metallic component and greater than 90%
dry solids content was made in a 2% aqueous solution (w/w) with
about 2 or 1% acetic acid (w/w) at 40.degree. C.
[0155] b) The solution of chitosan from a) above was degassed under
reduced pressure at up to about 500 mTorr under agitation for at
least 5 minutes and poured into a mold to a depth of 1.7 cm.
Certain low-density, foam structures exhibited problems due to
their ready dissolution in a bleeding field. These problems were
generally avoided by thorough degassing of the solution.
[0156] c) The mould containing the degassed chitosan solution was
frozen by cooling from room temperature to -45.degree. C. A linear
cooling ramp was used over a 90 minute period, and the temperature
was maintained at -45.degree. C. for at least another hour.
[0157] d) The frozen chitosan was then freeze dried using a
condenser which was at a temperature below -70.degree. C. and a
vacuum at about 100 mTorr. The shelf temperature was ramped from
-45.degree. C. to -15.degree. C. and held at that level for 10
hours. A further 36-48 hours of freeze drying at 10.degree. C. was
then performed. Freeze drying was performed until achieving close
to about 2.8% of the original frozen plaque mass.
[0158] e) At 2.8% of original mass, the process was stopped, and
the freeze dried wound dressing removed from the mold.
[0159] f) The product formed was an acid buffered, water soluble,
high specific surface area wound dressing that had shrunk 10% from
its original frozen volume. The wound dressing structure was
generally a uniform open porous structure with 50 to 80 micron
diameter interconnecting pores. Using a slightly different cooling
regime in which super-cooling was not affected, a lamella/hexagonal
structure (with uniformly thin chitosan sheets close to 5 microns
thick with close to 50 microns separation between sheets) was
achieved.
[0160] g) The wound dressing was then compressed (from 1.7 cm to
ca. 0.5 cm thick) between smooth and flat platens heated to
80.+-.2.degree. C. under application of 60.+-.20 kPa pressure.
[0161] h) Next, the dressing was conditioned in a convection oven
by heating at 80.+-.5.degree. C. for 30 minutes.
[0162] i) Each wound dressing was then stored in labeled Kapak 530
heat sealed pouches.
[0163] j) The resultant pressed wound dressing was tough, flexible,
hemostatic, adherent to wet tissue and resistant to dissolution by
streaming blood.
[0164] k) Improved dissolution properties, improved adhesion
strength and sterilization were achieved by exposure of the wound
dressing to 15 kGy gamma irradiation under nitrogen atmosphere.
[0165] In vivo evaluation of hemostasis of candidate hemorrhage
control dressings of varying composition and structure was screened
in increasingly challenging animal models of hemorrhage. A spleen
laceration model was utilized in order to be able to screen large
numbers of candidate dressings in a simple reproducible model and
to compare them to conventional materials. Although this is the
least challenging bleeding model (mild oozing bleeding ca. 2-5
mL/min), most initial wound dressing formulations failed this test.
Also all chitosan gels, powders failed in this test while films
performed poorly.
[0166] Prior to testing in a severe hemorrhage model, swine were
anticoagulated with systemic intravenous heparin and better
materials were tested in a capsulated spleen stripping model
(strong oozing bleeding ca. 10-20 mL/min). Those few materials that
passed this test were then evaluated in the carotid laceration
model (ca. 50 mL/min) in anticoagulated swine. Wound dressing
formulations of candidate materials passing this test were then
tested on the swine aortotomy model with in which 4 mm diameter
perforations in were made in the thoracic or abdominal aortas.
Materials passing these challenging models of severe vascular
hemorrhage (bleeding rates in excess of 100 mL/min) were also
tested in a severe (Grade V) model of hepatic trauma.
[0167] The testing was carried out on healthy animals that had
previously undergone procedures and were scheduled to be sacrificed
for evaluation. All experiments were performed in accordance with
the 1996 National Research Council, "Guide for the Care and Use of
Laboratory Animal" and applicable Federal regulations. After
identification of the animal, anesthesia was induced with Telazol
4-9 mg/kg intramuscularly (i.m.). Isoflurane was given by mask and
the animal was intubated.
[0168] The chitosan patches for the laceration and capsular
stripping experiments were either equal size quarter pieces cut
from a 37 mm diameter wound dressing or 1.5 cm.times.1.5 cm wound
dressing pieces cut from a larger wound dressing.
[0169] Control materials of Gelfoam.TM.+thrombin or Surgicel.TM.
were prepared from 1.5 cm.times.1.5 cm pieces. Gelfoam.TM. size
100, absorbable gelatin wound dressing, was supplied by Pharmacia.
Oxidized cellulose, Surgicel.TM., was supplied by Ethicon. Topical
thrombin (bovine origin) 10,000 U.S. units was supplied by Jones
Pharma. The Gelfoam.TM.+thrombin was prepared before use by soaking
of 1.5 cm.times.1.5 cm.times.0.8 cm wound dressings in the thrombin
for 30 minutes.
[0170] A midline ventral laporatomy was performed. The top half of
the spleen was exteriorized (apposing the surgical wound with towel
clamps). The surface was kept moist by the application of sterile
saline solution from a wet lap pad.
[0171] For anticoagulation, the right femoral artery was surgically
isolated and cannulated with a 6F sheath, allowing for collecting
blood samples. The activated clotting time (ACT) was measured
before administration of 5000 units of heparin intravenously, 10
minutes after administration of heparin and every 20 minutes
thereafter. If the ACT level was less than 200 seconds, 2000 units
of heparin were given and the ACT was remeasured after 10 minutes.
This was repeated until the ACT>200 seconds to ensure that the
animal was anticoagulated.
[0172] The area of splenic testing was demarcated and kept moist by
using the towel clamps and wet pads and only exposing the most
immediate untested surface. A single injury was made prior to the
application of a test patch, as follows:
[0173] (i) In the laceration model, the injury (8 mm long.times.4
mm deep) was made using a #11 surgical blade positioned in a
right-angled forceps so that 4 mm of blade was protruding.
[0174] (ii) In the capsular stripping model, the injury (5
mm.times.5 mm.times.4 mm deep) was made using the clamped #11 blade
and a pair of surgical scissors.
[0175] After making the injury, bleeding was allowed for 30
seconds. The surface blood was removed with gauze, following which
a test patch was applied digitally to the injury using a constant
uniform pressure for 30 seconds. The digital pressure was then
removed and the patch was observed for two minutes. At this stage,
the trial number was recorded. If observable rebleeding occurred,
the time to rebleed was recorded, and the next trial (30 second
bleed, clean away blood with gauze, 30 seconds digital pressure
followed by up to 2 minutes observation) commenced. The trial for a
test patch was complete when no rebleeding occurred in the 2 minute
observation period or if 6 trial rebleeds were observed. If the
wound continued to rebleed for 6 trial periods, then the failed
patch was removed and a Gelfoam+thrombin patch applied. A new
injury was made and another patch tested.
[0176] In the case of the carotid laceration model, chitosan
patches (37 mm.times.25 mm) were cut from the 37 mm diameter
compressed wound dressing or larger wound dressings. For facility
in application, some of the wound dressings had a top layer of 3M
9781 foam medical tape attached to the chitosan with 3M 9942 skin
adhesive. Gelfoam.TM.+thrombin was used as a control.
[0177] A vertical incision was made exposing a 10 cm length of
carotid artery. The fascia was retracted and the surrounding soft
tissue was dissected until the artery was supported on a flat base
of tissue. Tie-off sutures were placed proximal and distal to the
exposed artery. These were clamped and a 1.5 cm incision was made
longitudinally in the artery.
[0178] For anticoagulation, the right femoral artery was surgically
isolated and cannulated with a 6F sheath, allowing for collecting
blood samples. The activated clotting time (ACT) was measured
before administration of 5000 units of heparin intravenously, 10
minutes after administration of heparin and every 20 minutes
thereafter. If the ACT level was less than 200 seconds, 2000 units
of heparin were given and the ACT was remeasured after 10 minutes.
This was repeated until the ACT>200 seconds to ensure that the
animal was anticoagulated.
[0179] After making the incision, the artery was allowed to bleed
for 2 seconds and then was compressed for 1 minute. The compression
was removed and the ties were re-clamped. The area was flushed with
saline. The ties were unclamped 2 seconds before application of a
patch. Pressure was applied uniformly over the patch for 3 minutes.
If bleeding was observed within 30 minutes after application of
pressure, then another 3 minutes of pressure was re-applied. If the
patch was not adhering then it was replaced with a new patch. Each
re-application of pressure, or replacement of a patch of the same
type were treated as trial periods for that patch type. A trial for
a particular wound dressing was considered complete if no bleeding
was observed from around, or through the patch in a 30 minute
period. A material was rated on the number of trials it took to
achieve 30 minutes of hemostasis (no observable bleeding from the
wound).
[0180] In the case of swine aorta perforation, sample patches of
compressed chitosan wound dressing cut to 2.5 cm diameter pieces or
controls of 4".times.4" surgical gauze were used.
[0181] Either or both the abdominal and the thoracic aortas were
exposed by midline ventral laporatomies in the former and
sternotomies in the latter. The fascia and sternum were clamped and
ties were placed proximal and distal to the sites of incision.
While the tie-off clamps were applied, a #11 scalpel blade was used
to make a 3 mm incision through the wall of the aorta and a 4 mm
diameter Medtronic.TM. vascular punch was inserted through the
incision to make a 4 mm diameter hole in the aorta. The punch was
removed and the tie-off clamps released with digital pressure
applied to the hole.
[0182] The patch was held between thumb and forefinger with the
middle finger applying pressure to the hole in the aorta. The
pressure from this middle finger was released for 1 second before
application of the wound dressing to the bleeding field. The wound
dressing was held in place by firm pressure applied through the
forefinger to the patch over the aortic hole. The pooled blood that
escaped the wound during application of the patch was suctioned
away. After 3 minutes of digital pressure, the finger was removed
and the patch observed for any sign of continued bleeding and poor
adherence.
[0183] If continued bleeding or re-bleeding was observed in the
first 30 minutes after application of the patch, then a further 3
minutes of pressure was applied. If hemostasis was still not
complete, then another patch of the same wound dressing was
prepared, the old patch removed and a new trial commenced. A trial
was considered complete if no bleeding was observed from around or
through the patch in a 30-minute period. A material was rated on
the number of trials it took to achieve 30 minutes of hemostasis
(no observable bleeding from the wound). Control samples of gauze
were applied in the same manner as the chitosan wound dressing
during a trial.
[0184] All animals were euthanized while under anesthesia with an
injection of barbiturates (Euthasol, 1 mL/10 lb) via an auricular
vein. Animals were euthanized at the end of the experimental
procedure or prior to the end if the animal experienced any
untoward effects.
[0185] Tests were ranked from 0.0 to 6.0 according to the number of
trials necessary before hemorrhage control was achieved and the
time to rebleed (only in the case of the spleen trials). A test in
which only one trial was necessary and there was no rebleed was
ranked as 0.0. A test which required a second trial and the time to
rebleed of the first was 90 seconds was ranked: 1 1.0 + 120 - 90
120 = 1.25
[0186] (in the case of a spleen) or 1.0 in the other models.
[0187] A test which needed four trials to achieve hemostasis and
where the time to splenic rebleed in the third trial was 30 seconds
was ranked: 2 3.0 + 120 - 30 120 = 3.75
[0188] (in the case of a spleen) or 3.0 in the other models.
[0189] A sample that failed completely by rapid dissolution, lack
of adherence or uncontrolled bleeding was ranked 6.0+.
[0190] In summary, the worse the hemostasis, the higher the ranking
as defined by the following: 3 R = + Where = number of trials to
stop bleeding - 1 = A - time to rebleed ( s ) in previous trial A A
= time of trial ( s )
[0191] The results of the spleen studies are summarized in Tables
2, 3 and 4.
[0192] Table 2 illustrates the behavior of chitosan test samples
that were non-optimized with respect to composition and structure.
These non-optimized materials ranged from, worse to the
Surgicel.TM. negative control (Table 4), to comparable and to only
partially better. The presence of phosphate buffer solution
produced a poorly adherent, slowly hemostatic patch that was only
slightly more effective than Surgicel.TM.. The chitosan film was
moderately adherent, providing a reasonable seal to bleeding,
however it was only very slowly hemostatic as evidenced by the slow
welling of blood beneath its transparent surface. The earlier
trials generally showed signs of a low density foam in the top
surface of the molded wound dressing. It was found that this low
density foam was susceptible to dissolution and collapse if the top
surface of the wound dressing was applied to a bleeding field. It
was subsequently discovered that this foam effect could be avoided
by degassing of solutions before freezing. Low molecular weight
chitosan wound dressings (relative 1% solution viscosity<50 cps)
were found to be very susceptible to dissolution in a bleeding
field making them unsuitable for the patch application. The
glutamate counter anion produced softer wound dressings but at the
cost of producing wound dressings that were readily dissolved in a
severely bleeding field. Low density wound dressings (those less
than 0.05 g/cm.sup.3) with acetate counterions were also found to
be readily compromised by dissolution and collapse.
[0193] Table 3 shows the result rankings of the optimized chitosan
wound dressings of preferred composition and structure. These wound
dressings were composed of chitosan with higher molecular weights
(relative 1% solution viscosity greater than 100 cps) and had wound
dressing densities close to 0.12 g/cm.sup.3. In the moderately
bleeding spleen tests, the results for the optimized wound
dressings were found, using a Wilcoxon Rank Sum W Test, to be
indistinguishable from the positive control of Gelfoam.TM.+thrombin
(Z=-0.527, p=0.598). Using the same statistical method, the wound
dressings were shown to be significantly different from the poorly
performed Surgicel.TM. control (Z=-3.96, p=0.0001).
[0194] FIG. 6 demonstrates (via a H&E stained histological
section) the close adherence of the optimized chitosan wound
dressings patches to the spleen surface as well as the
agglutination of erythrocytes at the immediate vicinity of the
injury.
[0195] The rankings for the carotid injury model are summarized in
Table 5. In this model, the optimized chitosan patch performed very
well in trials 3, 5 and 6. The improvement in performance over the
first trials 1 and 2 was due to the application of the support
backing (3M 9781 foam bandage) to the immediate top surface of the
wound dressing. This backing enabled more uniform pressure to be
applied over the wound dressing and allowed for the person applying
the dressing to remove their fingers easily from the patch surface
without them sticking and inducing patch detachment from the wound.
The carotid model was used to investigate more severe arterial
bleeding conditions than were possible in the spleen injury model.
Gelfoam.TM.+thrombin was investigated as a possible positive
control but was found to dissolve in a highly bleeding field.
[0196] Table 6 summarizes the results of the aortic injury model.
Gauze bandage (4".times.4") was used as a control bandage. It was
found that the control was unable to stop severe bleeding in all
trial periods whereas the optimized chitosan aortic patches were
able quickly to stop and subsequently clot the very high level of
bleeding observed in this wound after only 1 or 2 applications of
the patch. The exact significance (two-tailed p=0.002) was
determined for the probability that there was no difference between
rankings of sample and control. On average the blood loss after
patch application was minimal (<50 mL) if the wound was stanched
on the first attempt. If a second attempt was required blood loss
after patch application was greater than 100 mL but less than 300
mL. On average less than 150 mL of blood was lost after patch
application in the case of the chitosan wound dressing while, in
the case of the 3 gauze control studies, more than 1 liter of blood
was lost for each animal. In the case of the chitosan wound
dressing study, survival was 100%, while in the case of the gauze
study, none (0%) of the animals survived. The chitosan patches
demonstrated continued hemostatic efficacy over the trial period of
30 minutes and until the animals were sacrificed which was
generally 1 to 2 hours later. FIG. 7 demonstrates a typical
chitosan patch sealing a severe thoracic wound. The lumen side
(showing the injury) of the resected aorta sealed by the patch in
FIG. 7 is shown in FIG. 8. FIG. 9 shows a photomicrograph of a
stained histological section taken through the injury of FIGS. 7
& 8. Evidence of strong clotting at the injury site was found
on removal and inspection of aortas on animal sacrifice (FIG. 9)
and, in the case of trial number 16, where after dislodging a patch
in a live animal (after more than 30 minutes of application) there
was no subsequent re-bleeding.
2TABLE 2 Sample Sample Sample Sample Sample Model Model Result
Result Animal Type Source Name Batch Form Anticoagulat. Injury Rank
Comments 1346 Chitosan Carbomer 9012-75-4 VA- PBS treat No
Laceration 4.0 Poor adhesion + slow hemostasis UY992 1346 Chitosan
Carbomer 9012-75-4 VA- Film type No Laceration 2.7 Adhesive + slow
hemostatic UY992 1345 Chitosan Carbomer 9012-75-4 VA- PBS treat No
Laceration 5.6 Poor Adhesion + poor hemostasis UY992 1338 Chitosan
Primex Chitoclear TM 752 Dense type Yes Laceration 3.1 Slow bleed
through low density defect in wound dressing 1338 Chitosan Pronova
G113 005-370- Dense type Yes Capsular 6.0+ Low MW Chitosan
dissolved 01 1338 Chitosan Pronova G113 005-370- Dense type Yes
Capsular 6.0+ Low MW Chitosan dissolved 01 1338 Chitosan Pronova
G213 511-583- Dense type Yes Capsular 6.0 Softer Chitosan Collapsed
01 1338 Chitosan Pronova G213 511-583- Dense type Yes Capsular 6.0
Softer Chitosan Collapsed 01 1441 Chitosan Primex Chitoclear BN 381
LD type, FF Yes Capsular 1.8 Good adhesion + initial small type
bleed through 1441 Chitosan Primex Chitoclear BN 381 Dense type, FF
Yes Capsular 1.8 Good adhesion + initial small bleed type Dense
type = Dense wound dressing (ca. 0.12 g/cm.sup.3) PBS treat = A
wound dressing neutralized by soaking in phosphate buffer saline
solution LD type = Low density wound dressing (ca. 0.03 g/cm.sup.3)
FF type = A fast frozen wound dressing Film type = A solvent cast
film (500 microns)
[0197]
3TABLE 3 Model Ani- Sample Sample Sample Sample Sample Anti- Model
Model Result Result mal Type Source Name Batch Form coagulat. Organ
Injury Rank Comments 1346 Chitosan Carbomer 9012-75-4 VA- Dense No
Spleen Laceration 0.0 Good adhesion + rapid hemostasis UY992 type
1404 Chitosan Primex Chitoclear BN 381 Dense No Spleen Laceration
0.0 Good adhesion + rapid hemostasis type 1404 Chitosan Carbomer
9012-75-4 VA- Dense No Spleen Laceration 0.0 Good adhesion + rapid
hemostasis UY992 type 1404 Chitosan Primex Chitoclear BN 381 Dense
Yes Spleen Capsular 0.0 Good adhesion + rapid hemostasis type 1338
Chitosan Primex Chitoclear TM 752 Dense Yes Spleen Laceration 0.0
Good adhesion + rapid hemostasis type 1338 Chitosan Primex
Chitoclear TM 752 Dense Yes Spleen Laceration 0.0 Good adhesion +
rapid hemostasis type 1338 Chitosan Primex Chitoclear TM 752 Dense
Yes Spleen Capsular 0.0 Good adhesion + rapid hemostasis type 1338
Chitosan Primex Chitoclear TM 752 Dense Yes Spleen Capsular 0.0
Good adhesion + rapid hemostasis type 1338 Chitosan Primex
Chitoclear TM 752 Dense Yes Spleen Capsular 0.0 Good adhesion +
rapid hemostasis type 1338 Chitosan Primex Chitoclear TM 752 Dense
Yes Spleen Capsular 0.0 Good adhesion + rapid hemostasis type 1344
Chitosan Pronova CL213 607-783- Dense Yes Spleen Capsular 0.0 Good
adhesion + rapid hemostasis 02 type 1344 Chitosan Primex Chitoclear
TM 752 Dense Yes Spleen Capsular 0.0 Good adhesion + rapid
hemostasis type 1441 Chitosan Primex Chitoclear TM 752 Dense Yes
Spleen Capsular 0.0 Good adhesion + rapid hemostasis type 1441
Chitosan Primex Chitoclear TM 752 Dense Yes Spleen Capsular 0.0
Good adhesion + rapid hemostasis type 1441 Chitosan Primex
Chitoclear TM 752 Dense Yes Spleen Capsular 0.0 Good adhesion +
rapid hemostasis type 1441 Chitosan Primex Chitoclear TM 752 Dense
Yes Spleen Capsular 1.3 Good adhesion + initial slight local type
bleeding 1478 Chitosan Primex Chitoclear TM 751 Dense Yes Spleen
Capsular 0.0 Good adhesion + rapid hemostasis type 1478 Chitosan
Primex Chitoclear TM 751 Dense Yes Spleen Capsular 0.0 type Mean
0.1 .+-.0.31 Dense type = Dense wound dressing (ca. 0.12
g/cm.sup.3)
[0198]
4TABLE 4 Sample Sample Sample Model Model Result Result Animal
Sample Type Source Name Form Anticoagulat. Injury Rank Comments
1338 Control Pharmacia Gelfoam + thr Sponge Yes Capsular 0.0
Satisfactory adhesion + rapid hemostasis 1344 Control Pharmacia
Gelfoam + thr Sponge Yes Capsular 0.0 Satisfactory adhesion + rapid
hemostasis 1344 Control Pharmacia Gelfoam + thr Sponge Yes Capsular
0.0 Satisfactory adhesion + rapid hemostasis 1441 Control Pharmacia
Gelfoam + thr Sponge Yes Capsular 0.0 Satisfactory adhesion + rapid
hemostasis 1441 Control Pharmacia Gelfoam + thr Sponge Yes Capsular
0.0 Satisfactory adhesion + rapid hemostasis Mean 0.0 .+-.0.0 1338
Control Ethicon Surgicel Gauze Yes Laceration 5.9 Very slow
hemostasis 1441 Control Ethicon Surgicel Gauze Yes Capsular 3.9
Very slow hemostasis and poor adhesion 1441 Control Ethicon
Surgicel Gauze Yes Capsular 5.9 Very slow hemostasis and poor
adhesion Mean 5.2 .+-.1.15
[0199]
5TABLE 5 Trial Sample Sample Sample Sample Sample Model Model
Result Result Number Animal Type Source Name Batch Form
Anticoagulat. Injury Rank Comments 1 1404 Chitosan Primex
Chitoclear BN 381 Dense Yes Laceration 3 First trial injury.
Profuse bleeding type at site prior to application, first 3
applications slowed bleeding, final application closed wound area
not initially covered. 2 1335 Chitosan Primex Chitoclear TM 752
Dense Yes Laceration 4 Non-backed sample. Problem with type
pressure application without damaging wound dressing in bleeding
field. 3 1335 Chitosan Pronova CL213 607- Dense Yes Laceration 0 3M
backing enabled pressure 783-02 type application without damaging
wound dressing. 5 1442 Chitosan Primex Chitoclear TM 752 Dense Yes
Laceration 0 3M backing + Good adhesion type & rapid
hemostasis. 6 1442 Chitosan Primex Chitoclear TM 752 Dense Yes
Laceration 1 3M backing + Good adhesion type & rapid
hemostasis. 4 1441 Control Pharmacia Gelfoam + Sponge Yes
Laceration 6+ Unable to stop bleeding as th Gelfoam dissolved in
bleeding field and was non- adherent. Dense type = dense sponge
wound dressing (ca. 0.12 g/cm.sup.3)
[0200]
6TABLE 6 Trial Ani- Sample Sample Sample Sample Sample Model Model
Result Number mal Type source Name Batch Form Anticoagulat. Aorta
Injury Rank Result Comments 1 1465 Chitosan Primex Chitoclear TM
752 Dense No Abdom. 4 mm No backing. Sealed for 4 type perfor. mins
then bled through. 2 1465 Chitosan Primex Chitoclear TM 752 Dense
No Abdom. 4 mm 0 3M backed. Sandwich type perfor. around Aorta.
Hemostatic & adherent after 30 mins. 3 1470 Chitosan Primex
Chitoclear TM 752 Dense No Thor. 4 mm 0 3M backed. Remaining type
perfor. hemostatic & adherent after 30 mins. 4 1468 Chitosan
Primex Chitoclear TM 752 Dense No Thor. 4 mm 0 3M backed. Remaining
type perfor. hemostatic & adherent after 30 mins. 5 1462
Chitosan Primex Chitoclear TM 752 Dense No Thor. 4 mm 1 3M backed.
First patch type perfor. Temporarily adherent. Second Patch
remaining hemostatic & adherent after 30 mins. 6 1460 Chitosan
Primex Chitoclear TM 752 Dense No Thor. 4 mm 0 3M backed. Remaining
type perfor. hemostatic & adherent after 30 mins. 7 1460
Chitosan Primex Chitoclear TM 752 Dense No Abdom. 4 mm 1 3M backed.
First patch type perfor. slipped off. Second Patch remaining
hemostatic & adherent after 30 mins. 8 1461 Chitosan Primex
Chitoclear TM 752 Dense No Thor. 4 mm 0 3M backed. Remaining type
perfor. hemostatic & adherent after 30 mins. 9 1461 Chitosan
Primex Chitoclear TM 752 Dense No Abdom. 4 mm 0 3M backed.
Remaining type perfor. hemostatic & adherent after 30 mins. 10
1469 Chitosan Primex Chitoclear TM 752 Dense No Thor. 4 mm 3 3M
backed. First 3 patches type perfor. slipped off. Fourth patch
remained hemostatic & adherent after 30 mins 11 1469 Chitosan
Primex Chitoclear TM 752 Dense No Abdom. 4 mm 0 3M backed. Sandwich
type perfor. necessary as aorta perforated above and below. 12 1467
Chitosan Primex Chitoclear TM 751 Dense No Abdom. 4 mm 1 3M backed.
First Patch type perfor. removed after bleeding through side in
first 5 mins. Second patch remained adherent & hemostatic over
trial 13 1467 Chitosan Primex Chitoclear TM 751 Dense No Abdom. 4
mm 1 3M backed. First Patch type perfor. removed after collapsing
in first 5 minutes. Second patch remained adherent & hemostatic
over trial 14 1398 Chitosan Primex Chitoclear TM 751 Dense No
Abdom. 4 mm 0 3M backed. Remaining type perfor. hemostatic &
adherent after 30 mins. 15 1398 Chitosan Primex Chitoclear TM 751
Dense No Thor. 4 mm 1 3M backed. First patch type perfor. slipped
off. Second Patch remaining hemostatic & adherent after 30
mins. 16 1399 Chitosan Primex Chitoclear TM 751 Dense No Abdom. 4
mm 0 3M backed. Remaining type perfor. hemostatic & adherent
after 30 mins. Knocked off while making second nearby injury after
40 minutes. Injury had completely clotted over. 17 1399 Chitosan
Primex Chitoclear TM 751 Dense No Abdom. 4 mm 2 3M backed. First 2
patches type perfor. slipped off. Third patch remained hemostatic
& adherent after 30 mins. 18 1479 Chitosan Primex Chitoclear TM
751 Dense No Abdom. 4 mm 1 3M backed. First patch type perfor.
slipped off. Second Patch remaining hemostatic & adherent after
30 mins. 19 1479 Chitosan Primex Chitoclear TM 751 Dense No Thor. 4
mm 2 3M backed. First 2 patches type perfor. slipped off. Third
patch remained hemostatic & adherent after 30 mins. Mean 0.7
.+-.0.89 20 1483 Control J&J Gauze No Abdom. 4 mm 6+ After 15
minutes animal perfor. became hypotensive and was euthanized 21
1489 Control J&J Gauze No Abdom 4 mm 6+ After 15 minutes animal
perfor. became hypotensive and was euthanized 22 1490 Control
J&J Gauze No Thor 4 mm 6+ After 15 minutes animal perfor.
became hypotensive and was euthanized Dense type = dense sponge
wound dressing (ca. 0.12 g/cm.sup.3)
EXAMPLE 3
Hepatic Hemorrhage Control in Swine Liver Model
[0201] The US Army Science and Technology Objective (STO) A,
Hemorrhage Control, was established in 2000 to advance the need for
hemorrhage control on the battlefield. The general strategic
objective of the STO can be summarized as the development of
products and methods that will reduce the number of deaths due to
hemorrhage in battlefield casualties. The requirements for
hemorrhage control products and methods were stated thus:
[0202] They must be practicable for use by one or more of the
following: self (wounded combatant), buddy (fellow non-medical
soldier who aids the wounded soldier), combat lifesaver, combat
medic, physician assistant, and battalion surgeon. They must be
practicable for use in far forward field conditions including
rugged terrain, limited visibility, and environmental extremes.
Products and methods must not require external electrical sources.
All devices must be man-portable and durable. It is expected that
products and methods that are useable far forward will also be used
at higher echelons of care. A specific strategic objective of the
STO is the development of new or improved hemostatic agents for use
on compressible hemorrhage under far forward field conditions. A
single product for use on compressible and non-compressible sites
is desired.
[0203] As part of STO, a study of hepatic hemorrhage control in a
swine liver model was conducted at the US-Army Institute of
Surgical Research (ISR) at Fort Sam Houston, San Antonio, Tex.
using the hemorrhage control bandage of this invention. The study
was conducted to determine the effect of the chitosan hemorrhage
control bandage on blood loss and survival in a standardized model
of severe venous hemorrhage and hepatic injury in swine. This model
has been used to study numerous other hemostatic bandages at
US-Army ISR.
[0204] Cross-bred commercial swine were used in this study. Animals
were maintained in a facility accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care,
International. This study was approved by the Institutional Animal
Care and Use Committee of the U.S. Army Institute of Surgical
Research, Fort Sam Houston, Tex. Animals received humane care in
accordance with the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health publication 86-23, revised
1996).
[0205] Animals were assigned randomly to receive either the
Chitosan bandages or Gauze sponges (see Table 7). Surgical
preparation consisted of the following: Animals were fasted 36-48
hours prior to the surgical procedure, with water allowed ad
libidum. After premedication with glycopyrrolate and a combination
of tiletamine HCl and zolazepam HCl (Telazol.RTM., Fort Dodge
Laboratories, Fort Dodge, Iowa), anesthesia was induced by mask
using 5% isoflurane. The swine were intubated, placed on a
ventilator, and maintained with isoflurane. Carotid arterial and
jugular venous catheters were placed surgically. Laparotomy was
performed and splenectomy and urinary bladder catheter placement
were completed. A rectal temperature between 37.0.degree. C. and
39.0.degree. C., and 15 minutes of stable mean arterial pressures
(MAP) were required prior to further experimental procedures. Blood
pressure and heart rate were recorded at 10-second intervals
throughout the study period using a continuous data collection
system (Micro-Med.RTM., Louisville, Ky.). Baseline arterial blood
samples were collected from each animal to confirm that each animal
exhibited normal platelet count, prothrombin time, activated
partial thromboplastin time, and plasma fibrinogen
concentration.
[0206] Liver injuries were induced. The method included the
following. The liver was retracted by manually elevating the left
and right medial lobes to allow adequate exposure. Next, a
specially designed clamp with two 4.5 cm sharpened tines configured
in the form of an `X` was positioned with the center approximately
2-3 cm dorsal to the intersection of the left and right medial
lobes, on the diaphragmatic surface of the liver. The base plate of
the instrument was positioned beneath the quadrate lobe, on the
visceral surface. The injury was induced by clamping the tines of
the instrument through the parenchyma and underlying vessels of the
two medial lobes so that the tines were seated in corresponding
grooves in the base plate of the instrument. After the first
penetration of the liver, the instrument was opened and the tines
were withdrawn and repositioned to the animals left such that the
second application would overlap the first by 50 percent. Following
this repositioning, the liver was penetrated a second time.
Documentation of the liver injury was achieved by excision and
inspection of the liver at the conclusion of the experimental
period. The injuries appeared as large stellate wounds with a small
island of tissue in the center, and measured approximately
10.times.8.times.4 cm. The injuries were through and through, with
one or more of the left medial lobar vein, right medial lobar vein,
and portal hepatic vein lacerated.
[0207] Thirty seconds after injury, resuscitation was initiated
with warm (38.degree. C.) lactated Ringer's solution in all
animals. The goal of resuscitation was return to baseline MAP.
Fluid was administered at 260 mL/min. This resuscitation regimen
was continued until the goal was reached and reinitiated if MAP
decreased, throughout the 60 minute study period. Simultaneously
with initiation of resuscitation (30 seconds post-injury),
treatments were applied as follows. One dressing was applied to the
surface of the quadrate lobe to cover the penetrating injury and
two other dressings were stuffed into the injury from the
diaphragmatic aspect. Compression was applied for 60 seconds in the
dorso-ventral direction. After 60 seconds, the injury was inspected
to determine whether hemostasis was achieved. Next, the
applicator's hands were repositioned and pressure was applied for
60 seconds in the latero-medial direction, and the observation for
hemostasis was performed. This sequence was repeated for a total of
four 60 second compressions. If hemostasis was complete after any
compression, no further compressions were performed. Hemostasis was
defined as the absence of visually detectable bleeding from the
injury site.
[0208] Following completion of treatment application, the abdomen
was closed and the animal was monitored for 60 minutes after injury
or until death, whichever came first. Death prior to 60 minutes was
defined as a heart rate of 0. At 60 minutes, surviving animals were
euthanized by an overdose of pentobarbital.
[0209] Immediately after induction of the injury, blood was
continuously suctioned from the peritoneal cavity until the start
of treatment application. The volume was determined and designated
as pre-treatment blood loss. At the end of the study period, each
abdomen was opened and the liquid and clotted intra-peritoneal
blood were suctioned and measured. This was designated as
post-treatment blood loss. Additionally, total resuscitation fluid
use was recorded. Pre-injury animal blood volume was estimated as
previously reported (Pusateri et al., Mil. Med. 166, 217-222,
(2001)).
[0210] Body weight, estimated blood volume, number of vessels
lacerated, baseline MAP, survival time, preinjury MAP, pretreatment
blood loss, and bandage adherence scores were analyzed by analysis
of variance using the GLM procedure of SAS. Data are reported as
least squares mean.+-.standard error of least squares mean. Data
were examined for heterogeneity of variance and non-normality.
These conditions were detected for post-treatment blood loss and
fluid use data. Therefore, blood loss and fluid use data were log
transformed prior to analysis. The transformed data were analyzed
by analysis of variance. These data are expressed as back
transformed means and 95% confidence interval (95% CI).
Distribution of females and males, hemostasis, and survival data
were analyzed by Fishers Exact Test using the FREQ procedure of
SAS. Data are reported as proportions or percentages. Two sided
tests were used for all comparisons.
[0211] There were no differences among treatment groups in animal
body weight, estimated blood volume, distribution of animal sexes,
baseline MAP, preinjury MAP, number of major vessels lacerated
within the liver injury, or pretreatment blood loss (See Tables 8
and 9).
[0212] Post-treatment blood loss was reduced in the Chitosan group,
compared to the Gauze wound dressing control (p=0.01). No
significant difference in fluid use was observed. Survival
percentage was increased in the Chitosan group (p=0.04). Hemostasis
occurred more frequently in the Chitosan group at 3 and 4 minutes
post-injury (p=0.03). Survival times could not be statistically
compared because of the high level of survival in the Chitosan
group (See Table 10).
7TABLE 7 Test Material Lot Number And Related Information Gauze
Dressing Johnson and Johnson NU Gauze Sponge General Use (Negative
10.2 cm .times. 10.2 cm. Rayon/Polyester Formed Fabric. Control)
Lot Number 1999-05 1399T5205B2. Chitosan Wound Oregon Medical Laser
Center, Chitosan Wound dressing dressing, 10.2 cm .times. 10.2 cm.
Lot Number 052101. Batch Number E1041. May 26, 2001 (1% AA, Primex
Lot # 751).
[0213]
8TABLE 8 Gauze Sponge P value of Variable Control Group Chitosan
Group difference N 7 8 N/A Body Weight (kg) 39.1 .+-. 1.2 38.7 .+-.
1.1 0.82 Estimated Blood 2819 .+-. 66 2800 .+-. 64 0.83 Volume (mL)
Female/Male (n/n) 5/2 6/2 0.88 Baseline MAP (mm Hg) 71.3 .+-. 3.6
68.8 .+-. 3.3 0.50 Preinjury MAP 69.1 .+-. 4.8 69.3 .+-. 4.4 0.98
(mm Hg) Hematocrit (%) 32.2 .+-. 1.1 32.6 .+-. 1.0 0.79 Hemoglobin
(g/dL) 11.2 .+-. 0.4 11.3 .+-. 0.3 0.80 Platelets (1000/.mu.l) 567
.+-. 28 502 .+-. 25 0.11 PT (sec) 10.7 .+-. 0.2 10.6 .+-. 0.2 0.70
APTT (sec) 15.7 .+-. 0.9 16.5 .+-. 0.9 0.56 Fibrinogen (g/dL) 159
.+-. 0.9 180 .+-. 8 0.10
[0214]
9TABLE 9 Gauze Sponge Chitosan P value of Variable Control Group
Group difference Number of Vessels Lacerated 1.86 .+-. 0.29 1.88
.+-. 0.27 0.96 Pretreatment Blood Loss 296.1 .+-. 55.4 291.1 .+-.
55.4 0.95 (mL) Pretreatment Blood Loss 10.6 .+-. 2.0 10.3 .+-. 2.0
0.94 (mL/kg body weight)
[0215]
10TABLE 10 Gauze Sponge Chitosan P value of Variable Control Group
Group difference Post-treatment Blood Loss 2879 264 <0.01 (mL)
(788-10,513; (82-852; 95% CI) 95% CI) Post-treatment Blood Loss
102.4 9.4 <0.01 (mL/kg body weight) (28.2-371.8) (2.9-30.3; 95%
CI) Fluid Use (mL) 6614 1793 0.03 (2,519-17,363; (749-4,291; 95%
CI) 95% CI) Survival (%) 28.6 87.5 0.04 Survival Time (min; 38.4
.+-. 5.8 10.0 N/A nonsurvivors only) (n = 5) (n = 1) Hemostasis at
1 Minute (%) 0 50 0.08 Hemostasis at 2 Minutes (%) 0 50 0.08
Hemostasis at 3 Minutes (%) 0 62 0.03 Hemostasis at 4 Minutes (%) 0
62 0.03
[0216] This US-Army ISR study (Pusateri et al. J. Trauma, 54,
177-182, (2003)) demonstrates, in an independent study, the
significantly improved performance of the chitosan wound dressing
over standard 4".times.4" gauze. The US-Army ISR has only been able
to demonstrate significantly improved performance over 4".times.4"
gauze in the stanching of severe blood flow in the case of the
dressing of this invention claim and in the case of a dry Fibrin
Thrombin wound dressing being developed by the Red Cross. The Red
Cross Bandage is costly, as well as being delicate and prone to
breakage.
EXAMPLE 4
Irradiation of Bandages
[0217] High molecular weight 4".times.4" chitosan hemorrhage
control dressings with 3M 9781 porous foam backing were prepared
from an Icelandic shrimp source (Genis Lot# SO1115-1). These were
prepared with 2% acetic acid and 2% chitosan solution using a
commercial freeze drying company to prepare a large sterile lot of
chitosan bandages (Lot# OMLC.sub.--2SM114). The bandages were
irradiated at 15 kGy under nitrogen. They were subsequently tested
for uniaxial tensile strength, burst strength, blood adsorption,
water adsorption as well as for sterility. Swine aorta perforations
were carried out on non-gamma irradiated samples in abdominal and
thoracic injuries. Seven patches were used. On average blood loss
after patch application was <50 mL. All patches were adherent,
wound sealing and hemostatic on their first application (7.times.0
rankings). All animals survived.
[0218] Both gamma-irradiated and un-irradiated bandages (Lot#
OMLC.sub.--2SM114) were tested with an in vitro burst pressure test
developed at Oregon Medical Laser Center in Portland Oreg. To
perform a burst test, a 25 mm diameter circular test piece of the
bandage is immersed in citrated whole blood for 10 seconds. The
test piece is then placed centrally over, and firmly held with
digital pressure, on a 4 mm diameter perforation in the side of a
50 mm diameter PVC pipe for 3 minutes. After this initial
attachment, fluid pressure inside the pipe is ramped at 4.5.+-.0.5
kPa.s.sup.-1, with pressure and time recorded at 0.1 second
intervals. Burst pressure is recorded as the maximum pressure
recorded prior to failure. An adhesive failure ranking is assigned
to assess the relative adhesiveness of the bandage to the test
site. The ranking system is separated into 3 distinct modes of
failure. A ranking of 1 is given to a test piece that is readily
separated from the PVC surface with no chitosan remaining adhered.
A ranking of 2 is assigned when the test piece is less readily
detached and some of the chitosan remains attached to the test
site. A ranking 3 is assigned when the test piece can only be
removed by cohesive separation of the bulk wound dressing from the
base structure which remains firmly fixed to the PVC surface.
[0219] The average burst pressure of gamma irradiated and
un-irradiated chitosan bandages (Mean.+-.SD, n=6) on a PVC
substrate using blood as wetting medium was 122.+-.1.9 kPa and
86.+-.20 kPa, respectively. The results were analyzed statistically
using a T-test (p=0.007). The average adhesive failure rankings of
gamma irradiated and un-irradiated chitosan alpha bandages
(Mean.+-.SD, n=6) on a PVC substrate using blood as wetting medium
were both 3.+-.0. FIG. 10 shows an image of a high ranking failure
where cohesive failure has occurred within the chitosan
structure.
[0220] The blood and water adsorption properties of the dressings
(Lot# OMLC.sub.--2SM114) were determined by immersing small test
pieces (ca. 0.02 g) in blood or water for 3.0 seconds. Difference
in mass before and after immersion was recorded. The average mass
of medium adsorbed in 3 seconds per one gram of wound dressing was
determined for gamma irradiated and un-irradiated chitosan samples
(n=4) using blood or water as the wetting medium (see FIG. 11). The
results were analyzed statistically using a one-way ANOVA with a
Tukey-HSD test, p=0.001. Gamma irradiation significantly reduced
the excessive adsorption of water in the case of the non-irradiated
material. Such excessive water adsorption would cause wound
dressing collapse (into a gel) with subsequent adhesive and
structural failure.
[0221] Tensile test pieces of the chitosan dressings (Lot#
OMLC.sub.--2SM114) were evaluated using a uniaxial Chatillon
Materials Testing Vitrodyne V1000 equipped with a 5 kg load cell.
Samples were cut into dog-bone pieces (15.+-.1 mm.times.6.5.+-.0.5
mm.times.5.+-.0.5 mm gauge.times.thickness.times.width) and held
between two clamps. The crosshead speed was 10 mm.s.sup.-1. Load
and displacement were recorded at 0.1 second intervals.
[0222] Tensile results of whole dressings are shown in Table 11.
There were no significant differences between gamma irradiated and
un-irradiated samples with respect to both stress and strain. There
was a small increase in Youngs modulus with irradiation at 15
kGy.
11TABLE 11 Youngs Modulus Ultimate Load* Ultimate Sample (Mpa) (kg)
Elongation No irradiation 1.8 .+-. 1.2 2.2 .+-. 0.2 0.9 .+-. 0.1 (n
= 5) Gamma irradiation 4.4 + 2.7 2.3 .+-. 0.2 0.85 .+-. 0.15 (n =
9) *Calculated for a 2.5 cm wide bandage
[0223] Fifty two 4".times.4" chitosan wound dressings (Lot#
OMLC.sub.--2SM114) were prepared cleanly. Of these 4".times.4"
wound dressings, 46 were packaged in a double pack envelope and
were sent to the IsoMedix facility in Ontario, Calif. for
irradiation with gamma radiation at a certified dose between 14-15
kGy. Boxed with these samples were a set of 8 Staphylococus aureus
(ATCC 29213) doped chitosan wound dressing bars
(1".times.0.21".times.0.21") cut from wound dressing 2SM114#1. Each
bar was inoculated with 100 microliters of 0.5 MacFarlane inoculum.
The Staphylococcus aureus was swabbed from a demonstrably active
control culture. A control set of 4 bars with no staphylococus was
also included. Control samples with no gamma radiation treatment
were kept in small sterile containers in heat sealed envelopes at
room temperature and in the dark (see Table 12 for a summary of the
controls).
12TABLE 12 Lot # Control # Pieces Dosed Gamma OMLC_2SM114 61 4 No
No OMLC_2SM114 55 4 No No OMLC_2SM114 65 4 Yes No OMLC_2SM114 77 4
Yes No OMLC_2SM114 74 4 No Yes OMLC_2SM114 71 4 Yes Yes OMLC_2SM114
58 4 Yes Yes
[0224] The 46 irradiated wound dressing packages were opened under
sterile conditions with sterile handling, an ethylene oxide sterile
adhesive coated foam backing (3M 9781 tape) was attached, a small
off-cut piece (ca. 1.2".times.0.2.times.0.12") of each wound
dressing and backing was removed for individual wound dressing
sterilization testing and the wound dressings were repackaged
inside the original inner pack by heat sealing. 40 of these wound
dressings were labeled with lot number and wound dressing number
and sent out for evaluation. The off-cut and control pieces were
given to the microbiology facility at St Vincent's PHS for
sterility testing.
[0225] The off-cut pieces and control pieces were placed
aseptically in labeled sample vessels (0.6" diam..times.5")
containing enriched thioglycolate growth media and incubated
aerobically at 35.degree. C. The culture media were examined at 7,
14 and 21 days for indications of growth. The samples were
subcultured in Tryptic Soy Agar (TSA) with 5% sheep's blood,
incubated at 35.degree. C. and examined for growth after 48
hours.
[0226] The individual cultures were analyzed by turbidity testing
and subculture swabbing. Absence of any growth in all the cultures
and all the subcultures at 7, 14 and 21 days was demonstrated, even
those cultures that were un-irradiated and dosed with
Staphylococcus aureus. Gram positive staining of particular
cultures confirmed these findings.
EXAMPLE 5
Preparation of Sponge
[0227] Table 13 lists the hydrophilic polymers acquired for
testing. Additional hydrophilic polymers include polylysine,
chondroitan sulfate, starch and hyaluronan. Aqueous solutions
(2.00% and 8.00% w/w) of ultrafiltered (Ametek) water and
hydrophilic powder were prepared in clean, 1 liter bottles
(Nalgene). Non-woven chitosan matting (PolyMed, Inc.) was converted
into chitin non-woven matting by exposure to acetic anhydride
(Aldrich 99%) over 48 hours at room temperature. Residual acetic
anhydride was washed from the matting using multiple washings of
ultrafiltered water. Exposure of the acetylated matting to NaOH
(0.5 M) for 6 hours at room temperature hydrolyzed acetyl esters at
the 3 and the 5 glucopyranose carbons without any hydrolysis of the
acetyl amide at the carbon-2 position (verified by FTIR analyses).
A twisted (1/cm) ultrafine (4 micron diameter) multi-filament
(>50) polyester yarn (200 micron under 20 N load) was acquired
(Multicraft Plastics, Portland, Oreg.).
13TABLE 13 Hydrophilic Polymer Source Specific Information Chitosan
Primex Food grade product, Degree of (Iceland) deacetylayion >
85%; Brookfield viscosity at 25.degree. C., 1% aqueous solution, 1%
acetic acid > 300 cps; protein < 0.2% Carboxy methyl Aldrich
Catalogue # 419281 Cellulose Polyacrylic Acid Aldrich Catalogue
#306215 Alginic acid Aldrich Catalogue # 180947 Dextran Aldrich
Catalogue # D5501
[0228] Glacial acetic acid (Aldrich 99.99%) was added to the 2% and
8% chitosan aqueous solutions at 2% and 4% w/w of water
respectively. Dissolution of the hydrophilic polymer solutions was
achieved by slow axial rotation of the bottles at room temperature
for up to 24 hours on a rotary bed stirrer. All the 2% solutions
went readily into solution, with the highest viscosities measured
by a LVT Brookfield viscometer at 25.degree. C. and number 2 and
number 3 spindles at less than 2000 cps. The 8% solutions of
chitosan, alginic acid and acrylic acid had viscosities too high
for measurement by the Brookfield viscometer. The very high
viscosity fluid solutions in these instances prevented the
solutions from being poured. Instead, the solutions were squeezed,
pulled and scooped from their plastic bottles to load the molds.
These latter very high viscosity fluids could not be readily
processed in a manufacturing environment.
[0229] Sponges were formed by pouring/placing aqueous solutions
into Teflon.TM.-coated, 10.8 cm.times.10.8 cm.times.2.0 cm wells in
aluminum molds to 1.7 cm deep in the case of 2% aqueous solutions
or 0.45-0.70 cm deep in the case of 8% solutions. The solutions,
initially at room temperature, were frozen into plaques by
placement of the aluminum molds on cooling shelves at temperatures
between -25.degree. C. and -45.degree. C. for 3 hours in laboratory
(0.65 m.sup.2) Virtis or (3.72 m.sup.2 or 16.63 m.sup.2) Hull
freeze dryers. Sublimation of water from the plaques to produce
hydrophilic polymeric sponges was accomplished by freeze-drying at
less than 200 mTorr pressure, condenser at -80.degree. C. with
shelf temperature ramped slowly from -45.degree. C. to 18.degree.
C. over 48 to 60 hours.
[0230] In the case of a sample of the 2% chitosan solutions, 4
strategies were tested to stop unwanted crust (top surface ice
nucleation) formation in 2% chitosan solutions during freezing. One
method was to place a thin polymer film over the top surface of the
molds and in intimate wetting contact with the surface of the
polymer solution prior to placement on the cold shelf for freezing.
After the solution had been frozen into a plaque (ca. 1-2 hours),
the thin protective polymer film is removed. Polyvinylidene
chloride film (e.g., Saran.TM. wrap) is particularly useful,
because its glass transition temperature is below -45.degree. C.
The thin film acts to stop dendritic ice formed on cold surfaces
within the freezer/freeze dryer from depositing onto the top
super-cooled hydrophilic polymer solution surface and nucleating a
frozen surface crust. The second approach to prevent this crust
layer was the use of an elevated (using 250 mm.times.6 mm.times.5
mm spacer bars) thin (e.g., 3 mm) acrylic plate place immediately
above the mold. This had advantages over the thin film method,
because it was not necessary to interrupt the freezing/freeze dryer
cycle to remove the contacting thin protective polymer film. A
third method, detailed in Example 7, used a permanent permeable
chitin non-woven mat backing application on the top surface of the
poured mold solutions. A fourth approach, detailed in example 11,
was to use heat sealed, foil-lined pouches filled with hydrophilic
solution as the solution containment during freezing.
[0231] At the completion of freeze drying (>48 hours), sponges
were removed from the dryer, weighed and stored in heat sealed
foil-lined pouches. The sponges were 10 cm.times.10 cm.times.1.7 cm
in the case of solutions poured to 1.7 cm depth and 10 cm.times.10
cm.times.0.43 cm in the case of sponges poured to 0.45-0.7 cm
depth. Moisture analysis using an Arizona Instruments Vapor Pro
moisture analyser demonstrated % residual moisture at between 1%
and 4% of sponge mass. Residual acetic acid in chitosan sponges was
determined using a Mettler DL53 autotitrator and 0.010 M NaOH at
between 27% and 22% sponge mass. Mean sponge densities for 2% and
8% solution chitosan sponges were 0.031.+-.002 g/cm.sup.3 and
0.103.+-.0.014 g/cm.sup.3 respectively. Mean sponge densities for
the other hydrophilic sponges were 0.0248.+-.0036 g/cm.sup.3 for
the 2% sponges and 0.0727.+-.0023 g/cm.sup.3 for the 8% sponges.
The mean 29% density difference between chitosan sponges and the
other hydrophilic sponges is caused predominantly by the acetic
acid in the chitosan sponges and a small fraction of volatile
component not taken into account when weighing the non chitosan
sponges.
[0232] The 2% sponges from all the different hydrophilic test
polymers were all well formed, compliant and of similar appearance
and structure. All shrank by close to 8% in the width and length.
The alginate and chitosan sponges had very good cohesive
properties, resisting tearing and cracking with manipulation. The
dextran, carboxy methyl cellulose and polyacrylic acid sponges were
less cohesive, readily cracking and tearing with manipulation. The
typical appearance of a 2% sponge frozen at close to -30.degree. C.
is shown in FIG. 12. The edges appeared smooth and decorated with a
regular mosaic structural pattern. The top side of the sponge was
slightly domed in its center. The only apparent feature was a
regular 0.5 mm diameter.times.0.5 mm deep surface pocking. The base
surface (i.e., the surface in contact with the Teflon.TM. mold
base) exhibited a surface texture and apparent "large single
crystal" regions separated by grain boundaries. A transverse
cross-section cut using single sided safety razor blades (FIG. 13)
demonstrates the internal structure. The grain boundaries in the
base surface can be seen as boundaries demarcating regions of fine
lamella oriented in different directions and likely originating
from different heterogeneous nucleating events at the mold surface.
The sponge internal structure can be described by a base layer of
fine lamella (each 2-5 microns thick) that extends up into the
sponge and encompasses close to 60% of the thickness of the sponge.
Immediately above the base lamella is a thin interface (<10
microns) that separates the base fine layer from the top course
layer. This course layer originates from foreign dendritic ice
contacting top surface solution when the top solution temperature
falls below 0.degree. C. The lamella in this layer are greater than
10 microns thick and are generally oriented vertical to the top
surface. These course, vertical lamella resist compression normal
to the plane of the sponge. The chitosan sponges formed by
protecting the top surface from nucleation with dendritic ice did
not have a top crust structure. These sponges had improved
mechanical performance in terms of resistance to cracking, and
improved compliance (flexibility) compared to sponges formed with
no top surface protection.
[0233] All surfaces of the 2% sponges readily adsorbed blood or
water. All the uncompressed sponges were highly susceptible to
collapse into a gel if they were contacted with excess water or
blood for short periods of time (i.e., 5 seconds or greater).
[0234] The 8% sponges were considerably more rigid than the 2%
sponges. Fine structure could not readily be observed in the sponge
base, which appeared closed and smooth. These sponges did not
adsorb blood and water as readily as the compressed 2% sponges. On
cutting transverse sections of these sponges, it was observed that
the internal structure was not unlike that in the 2% sponges: the
course top vertical structure was present at close to the same
relative depth as in the 2% sponge (i.e., 30-40%), and the base
layer was composed of highly compact zones of lamella oriented near
30.degree. from the normal and demarcated by fine grain
boundaries.
[0235] Sponges from 2% solution were typically pressed by heating
Teflon.TM. coated parallel plate platens to 80.degree. C., and
bringing the platens together to a constant spacer distance
(typically 0.55 cm) at a constant rate of between 1200 mm/min to 5
mm/min. Sponge density of a 1.70 cm thick sponge pressed to 0.45 cm
was approximately 0.10 g/cm.sup.3. Sponges pressed at less than
80.degree. C. and/or greater than 20 mm/min compression rate were
susceptible to mechanical failure by cracking at grain boundaries
and by brittle failure. This was found in the case of 2%, 1.7 cm
thick chitosan sponges pressed at greater than 60 nun/min. Of 864
sponges, more than 260 sponges were discarded due to brittle
collapse and failure. When the compression rate was adjusted to 20
mm/min there were only 43 discards from 864 sponges. When the
compression rate was adjusted to 10 mm/min, there were less than 9
discards.
[0236] The change in sponge structure on pressing at slow rates
(<12 mm/min) is shown in FIG. 13. It can be seen that the fine
base lamella oriented at between 20.degree. and 40.degree. to the
vertical are readily densified (75% compression) to a uniform base
layer, while the vertical course top layer is only partially
densified (ca. 55% compression). At slow compression rates, the
grain boundary regions remain in intimate contact. At higher rates
of compression (>20 mm/min), the grain boundary regions are more
likely to separate.
[0237] The (observation with respect to hydrophilic sponges)
compressed sponges were less easily wetted by water or blood and
they were more resistant to dissolution in both media. The
compressed 2% sponges, although well wetted by blood did not
dissolve. Adhesive strength of wetted compressed sponges was rated
as PAA>Chitosan>CMC>Alginic acid.
[0238] A very important determinant of an efficacious sponge is the
presence of micron size crenulations (FIG. 14) orthonormal to the
surface of the lamella. These crenulations protrude 3 to 10 microns
from the lamella surface as small "teeth". Ideally they should be
regularly distributed on at least one surface of the lamella. These
structures are most common under controlled conditions when lamella
are forming at orientations of lamella growth greater than
30.degree. to the vertical. Also they appear to be controlled by an
ability to rapidly cool the frozen plaque to less than -45.degree.
C. after the initial 30 to 60 minute period of freezing at
-25.degree. C. After pressing, test chitosan sponges were baked in
a constant temperature convection oven at 80.degree. C. for 30
minutes to anneal residual stresses and remove free acetic acid
residue.
EXAMPLE 6
Preparation of 2% Chitosan Sponges
[0239] A. Two samples of 2% chitosan sponges (N=3): one sample
pressed from 1.7 cm to 0.55 cm at 20 mm/min while the other was not
pressed. Both samples were baked at 80.degree. C. for 30 minutes.
Square test pieces (5 cm.times.5 cm) were cut from each sponge. A
test piece was wetted with citrated porcine whole blood by 10
second submersion in blood at room temperature. It was attached
centrally over a 4 mm diameter perforation in a 10 cm.times.10 cm
surface of 12 mm thick, clear PVC (roughened using 400 grit wet and
dry paper) by digital pressure (200-300 mmHg) for 3 minutes.
Porcine whole blood at room temperature in a reservoir beneath the
perforation was ramped in pressure (near 50 mmHg/s). A pressure
transducer was attached to the reservoir to measure maximum
pressure at failure.
[0240] Sponge test pieces (N=3) that were pressed held pressure to
greater than 500 mmHg. Failure in these sponges was by loss of
adhesive binding to the PVC. Sponge test pieces that had not been
pressed (N=3) failed at less than 500 mm Hg and failure was by
sponge collapse and dissolution in the blood.
[0241] B. Two percent solution chitosan sponges (N=5) pressed from
1.7 cm to 0.55 cm at 10 mm/min; baked at 80.degree. C. for 30
minutes; backed with foamed PVC tape and sterilized with gamma
radiation (15 kGy). Test pieces (5 cm.times.5 cm) were submersed in
porcine whole blood at room temperature for 10 seconds. The test
piece was then attached centrally over a 4 mm diameter perforation
on a flat PVC surface and held with loading pressure (near 600 mm
Hg) for 3 minutes. At the end of this period, porcine whole blood
at room temperature beneath the perforation was ramped to pressure
(near 50 mmHg/s) to 300 mm Hg for 3 minutes and then again ramped
at a similar rate until the attached test piece failed. Test piece
failure occurred when the blood pressure was greater than 1800 mm
Hg. Failure was either by cohesive rupture, dissolution of top
crust layer or adhesive loss of binding to the PVC.
[0242] C. A chitosan sponge test piece (4 cm.times.4 cm.times.0.5
cm) prepared from 8% solution was found to be effective at stopping
bleeding in a 4 mm diameter acute swine aorta perforation (mean
arterial blood pressure 70 mm Hg; bandage test piece hemostatic for
longer than 30 minutes). However sponges from the 8% chitosan
solution were inflexible and could not be readily conformed to a
wound. On the other hand, sponges of the same density, formed from
2% solution chitosan solutions but pressed from 1.7 cm to 0.45 cm
were not only effective at stopping the bleeding in this aorta
perforation injury, but were also readily compliant and became more
compliant with time when placed against the bleeding wound.
[0243] D. One inch diameter test pieces (N=12) from slow compressed
(1.70 cm to 0.45 mm) initially 2% solution chitosan bandages formed
from crust free sponges were attached (digital pressure for 3
minutes to initially free flowing bleeding, mean arterial pressure
at 70 mm Hg) to perforated (4 mm diameter) aortas in 12
anaesthetized swine. All test pieces staunched bleeding on the
first application and were hemostatic over at least 30 minutes. In
comparison, chitosan bandages formed from bandages with a crust
layer (N>100) took on average 0.5 to 1.5 re-applications of
pressure to staunch bleeding over the same time period.
[0244] E. Oval (3.8 cm.times.3.2 cm) test pieces (N=10) of fast
pressed (>50 mm/min) 2% chitosan sponges were submersed in
porcine whole blood at room temperature for 10 seconds. The test
pieces were then attached centrally over a 4 mm diameter
perforation on a flat PVC surface and held with digital pressure of
500 mm Hg for 3 minutes. At the end of this period, porcine whole
blood at room temperature beneath the perforation was pressurized
(at near 50 mm Hg/s) to 300 mm Hg/s for 3 minutes and then again
ramped (at about 50 mm Hg/s) until the test pieces failed. Failure
was ranked in terms of maximum pressure attained, final adhesion to
the test fixture, and bulk sponge cohesion after failure. This
result was compared to the results of similar testing of 20 test
pieces of 2% chitosan sponges that were slow pressed (compression
rate<15 mm/min). The final burst and adhesion rankings were
similar; however 60% of the fast pressed sponges had the lowest
possible cohesion rankings due to gross crust dissolution and
gelation while all 20 of the slow pressed bandages had the highest
cohesion rankings.
[0245] F. Two sets of 2% chitosan sponges were prepared. One set
had substantial lamella surface crenulations, another set had no
crenulations on the lamella surfaces. Both sets of sponges were
pressed at slow pressing rates to close to 0.10 g/cm.sup.3 density.
Sponges were baked at 80.degree. C. for 30 minutes and backed with
PVC foam film. In swine aorta perforation experiments, the set of
sponges with crenulated lamella were effective in staunching severe
arterial bleeding in all cases (N=12). In sponges without
crenulated lamella (N=6), no test pieces were effective in
staunching bleeding.
EXAMPLE 7
Preparation of Chitosan Sponge with Chitin Mesh Reinforcement
[0246] A chitin non-woven mesh soaked in water was placed against
absorbent wipes (Kimwipe.TM.) to reduce the amount of water in the
non-woven chitin mat. The mat was cut to a 10 cm.times.10 cm
square. It was then placed on the surface of a 2% chitosan solution
that had been poured into a 10.8 cm.times.10.8 cm.times.2 cm deep
aluminum mold well. It was observed that the mat remained suspended
at the surface of the chitosan and that there was some adsorption
of chitosan superficially into the mat. The chitosan solution and
the mat were placed in the laboratory (Virtis) freeze dryer. The
solution was frozen, and the water sublimed to reveal a sponge with
a woven mat firmly attached at its surface. The sponge with the
chitin matting dried at the same rate as a sponge with no chitin
matting. A section of the chitin backed sponge was transverse
cross-sectioned to reveal partial infiltration of the chitosan into
the matting to close to 1.5 mm deep. However, the section also
revealed that the top 1 mm of the mat surface was free of chitosan.
The sponge with the chitin mat composite surface was pressed at 20
mm/min between parallel plate platens heated at 80.+-.2.degree. C.
from 1.8 cm to 0.45 cm thickness. Transverse cross-sectioning
through the sponge after pressing demonstrated that the interface
between the chitin mat and the chitosan sponge had not been damaged
by the pressing and that both mat and sponge were firmly fixed
together. Also the presence of the chitin mat had stopped the
formation of sponge crust (course ice nucleation from the top
surface down) that can affect sponge compliance and sponge
resistance to dissolution. The sponge was tested in an acute swine
4 mm diameter aortic perforation model. Bleeding in this injury was
not being stopped by regular chitosan bandage pieces and the chitin
mat backed test piece was applied by holding digital pressure for 3
minutes. The surgeon applying the 2.5 cm diameter test piece noted
that the test piece was particularly compliant and that he could
remove his finger without it sticking to the chitin backing. The
test piece sealed the injury site for more than the required 30
minute test period of the protocol. It remained well adhered to the
injury site and showed no signs of dissolution even though it did
not have the protective impermeable backing normally applied with
this bandage. Also, it was observed that the bandage was compliant
on the injury as it was possible to observe a pulse through the
flexing of the bandage.
EXAMPLE 8
Chitosan Impregnated Thread
[0247] The 0.5 mm diameter polyester multifilament submerged in 2%
chitosan solution expanded to ca. 2 mm in diameter. The chitosan
soaked thread at room temperature was then gently rested on a flat
hydrophobic Teflon coated aluminum tray without drawing any of the
solution out of the expanded thread. The tray was then placed on
the Virtis Freeze dryer shelf at -25.degree. C. and allowed to
freeze. The ice was removed from the thread by freeze drying
leaving a 2 mm diameter expanded thread impregnated with chitosan
sponge at 0.033 g/cm.sup.3. Application of a tensile force of close
to 10 N to the expanded thread and pressure of about 500 mm Hg
normal to the thread surface through a tapered nitrile rubber,
non-stick pinching die compressed the thread diameter from 2 mm to
about 0.7 mm. The thread exhibited good compliance and was prepared
for weaving into a gauze-like dressing. A portion of the thread was
baked at 80.degree. C. for 10 minutes. It was then submersed in
blood for 10 seconds and held firmly against a clean test PVC
surface for 3 minutes. It demonstrated good adhesion.
EXAMPLE 9
Comparative Flexure Between Compressed Low Density Sponges and
Non-Pressed High Density Sponges
[0248] The method of densification presented here reduces a highly
compliant low density interconnected sponges in volume by a
controlled reduction in thickness, width and/or radius. Preferably,
the compliance of the hydrophilic polymers is not modified with
plasticizers such as glutamic acid or glycerol, because this
modification renders the sponges more susceptible to dissolution
and sponge collapse under severe bleeding. This example shows that
compression of low density sponges to higher density sponges
results in sponges of lower elastic modulus than if the sponge of
the chemically identical higher density had been formed without
densification.
[0249] In order to determine elastic modulus (E), deflections from
the horizontal were determined in single, cantilever beam
experiments. Rectangular beams were cut from pressed 2% sponges and
non-pressed 8% sponges. The beams were 9 cm long, and 2.54 cm wide.
They were anchored so that only 6.7 cm of the beam extended from
the edge of a flat horizontal surface. A 20 g or 30 g weight was
placed on the beam tip at 6.5 cm from the anchor point. The
deflection of the 6.5 cm point of the beam normal from the
horizontal was measured 3 seconds after loading. Elastic modulus
(E) was determined from the equation:
E=P.L.sup.3/(3y.I)
[0250] where I=w.h.sup.3/12
[0251] P=load (N); L=free beam length (m); y=beam deflection from
the horizontal (m); w=beam width (m); h=beam height in the vertical
plane (m); I=moment of inertia (m.sup.4)
[0252] The thickness of the beam was determined using a digital
caliper. After determination of beam deflection, the beam was cut
into 2.54 cm.times.2.54 cm squares, weighed and density determined.
The results of the testing are shown in Table 2. It can be seen
that the 8% samples are all more resistant to flexure than the 2%
samples. The mean elastic moduli (MPa) for compressed 2% sponges
are 6.43.+-.3.3, 1.75, 3.5 and 2.9.+-.0.4 for chitosan, polyacrylic
acid, carboxy methyl cellulose and alginic acid respectively. The
mean elastic moduli (MPa) for 8% sponges are 10.6.+-.3.3, 12.4,
4.54 and 5.7.+-.2.1 for chitosan, polyacrylic acid, carboxy methyl
cellulose and alginic acid respectively. The ratio of mean elastic
moduli of pressed 2% sponges over 8% sponges is 0.61, 0.14, 0.77
and 0.51 for chitosan, polyacrylic acid, carboxy methyl cellulose
and alginic acid respectively.
14TABLE 14 Beam Beam Sponge Deflec- Mass thick- Elastic % Test
density tion Loaded ness Modulus Polymer Soln # g/cm.sup.3 (mm) (g)
(mm) (MPa) Chitosan 2 1 .096 9 30 5.45 8.73 2 2 0.107 8 30 5.45
9.83 2 3 0.094 23 30 5.45 3.42 2 4 0.090 21 30 5.45 3.74 8 1 0.093
5 30 7.2 6.82 8 2 0.093 2 30 8.5 10.36 8 3 0.092 1.5 30 8.4 14.31 8
4 0.115 1.5 30 8.6 13.34 8 5 0.121 2.5 30 8.6 8.00 PAA 2 1 0.071 30
20 5.45 1.75 8 1 0.071 2 20 7.0 12.37 CMC 2 1 0.079 15 20 5.45 3.49
2 2 0.086 15 20 5.45 3.49 8 1 0.074 10 20 6.1 3.74 8 2 0.076 7 20
6.1 5.34 AA 2 1 0.078 15 20 5.6 3.22 2 2 0.077 15 20 5.7 3.05 2 3
0.074 20 20 5.6 2.42 8 1 0.071 6 20 5.6 8.05 8 2 0.074 7 20 6.3
4.85 8 3 0.070 7 20 6.6 4.22 PAA = polyacrylic acid, CMC = carboxy
methyl cellulose, AA = alginic acid
EXAMPLE 10
[0253] Pressed two percent solution, composite polyacrylic acid
sponges (N=2) test pieces (5 cm.times.5 cm) were submersed in
porcine whole blood at room temperature for 10 seconds. The test
piece was then attached centrally over a 4 mm diameter perforation
on a flat PVC surface and held with loading pressure (750 mmHg) for
3 minutes. At the end of this period, porcine whole blood at room
temperature beneath the perforation was ramped to pressure (near 50
mmHg/s) to 300 mmHg for 3 minutes and then again ramped at a
similar rate until the attached test piece failed. Test piece
failure occurred when the blood pressure was greater than 2300
mmHg. Failure was by sponge cohesive rupture.
EXAMPLE 11
[0254] An approach to achieve very good thermal contact with
freezing shelves, stop course crust formation during freezing and
to apply a controlled level of shear normal to growing vertical
lamella is described. Heat sealed, foil-lined pouches (15
cm.times.23 cm) were filled with 200 g of 2% chitosan solution. All
air was removed from the pouch prior to final sealing. The pouches
were placed in a laboratory Virtis freeze dryer between parallel
plate shelves at -25.degree. C. to freeze for at least 180 minutes.
The Virtis dryer had a "stoppering" facility which enabled the
upper shelf to be brought down onto the lower shelf and hence to
firmly contact and apply a loading to the chitosan filled, foil
pouches placed between spacers on the lower shelf. The pouches were
filled to a level such that when the upper shelf was lowered onto
the bottom one, the upper shelf rested firmly on the top surface of
the solution filled pouch. The extent of pressure on the pouch
could be controlled by the free weight of the top shelf and by the
number of pouches resting between the two shelves. In this example,
1.7 cm spacer bars were used, only 2 pouches were placed between
shelves and the load on the pouches was close to 10 kg. Prior to
freeze drying, the stoppered shelves were raised; the frozen
plaques removed from their pouches and placed on the cold freeze
dryer shelves. Expansion inside the pouches on freezing was
accommodated by partial internal rending of the heat seal. The
plaques were subsequently freeze dried into sponges. Transverse
sectioning through the sponges demonstrated uniform lamella
structure growing from top and bottom surfaces and meeting in the
middle of the sponges. The top structure was the mirror image of
the bottom structure. The lamella were all uniformly oriented at
between 20.degree. and 30.degree. to the vertical and in the
direction away from the center to the edge of the sponge. The
sponges demonstrated an absence of grain boundaries. The sponges
were pressed from 1.7 cm thickness to 0.55 cm. They had excellent
mechanical properties in terms of tensile strength, compliance and
resisting to tearing or fracturing on severe bending. The sponges
were baked, backed with PVC foam backing and gamma irradiated at 15
kGy.
[0255] A single oval test piece was applied to an aorta perforation
in the acute swine model. This was effective in stopping arterial
bleeding over the 30 minute test period. The surgeon noted that the
sample had very good compliance.
EXAMPLE 12
[0256] A simple positive textured surface was created on a 10
cm.times.10 cm.times.1.7 cm chitosan sponge. This was achieved
using a negative patterned 10 cm.times.10 cm.times.0.25 cm aluminum
card. The pattern was made by running a 400 grit wet and dry paper
over the flat aluminum surface. This surface was coated with a
non-permanent red dye most of which was removed from the top
portion of the surface by wiping with a dry cloth. A chitosan
sponge compressed against this surface demonstrated the positive
surface patterning as that revealed by the red dye in the aluminum
card.
[0257] All references discussed above are herein incorporated by
reference in their entirety for all purposes. While this invention
has been particularly shown and described with references to
preferred embodiments thereof, it will be understood by those
skilled in the art that various changes in form and details may be
made therein without departing from the spirit and scope of the
invention as defined by the appended claims.
[0258] The corresponding PCT application, International Application
No. PCT/US02/18757, filed on Jun. 14, 2002, is incorporated by
reference herein in its entirety for all purposes.
* * * * *